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Abstract
Recent advances in skin-resident adult stem/progenitor cell research have revealed that these immature and regenerative cells with
a high longevity provide critical functions in maintaining skin homeostasis and repair after severe injuries along the lifespan of individuals. The establishment of the functional properties of distinct adult stem/progenitor cells found in skin epidermis and hair follicles and extrinsic signals from their niches, which are deregulated during their aging and malignant transformation, has significantly
improved our understanding on the etiopathogenesis of diverse human skin disorders and cancers. Particularly, enhanced ultraviolet radiation exposure, inflammation and oxidative stress and telomere attrition during chronological aging may induce severe DNA
damages and genomic instability in the skin-resident stem/progenitor cells and their progenies. These molecular events may result
in the alterations in key signalling components controlling their self-renewal and/or regenerative capacities as well as the activation
of tumour suppressor gene products that trigger their growth arrest and senescence or apoptotic death. The progressive decline in
the regenerative functions and/or number of skin-resident adult stem/progenitor cells may cause diverse skin diseases with advancing age. Moreover, the photoaging, telomerase re-activation and occurrence of different oncogenic events in skin-resident adult
stem/progenitor cells may also culminate in their malignant transformation into cancer stem/progenitor cells and skin cancer initiation and progression. Therefore, the anti-inflammatory and anti-oxidant treatments and stem cell-replacement and gene therapies as
well as the molecular targeting of their malignant counterpart, skin cancer-initiating cells offer great promise to treat diverse skin disorders and cancers.
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Introduction
Human skin epidermis and its appendages exhibit different site-specific morphologies and very important physiological functions
including the protection against environmental injury, infection and
excessive dehydration, corporal temperature regulation, and hair
growth maintenance [1–6]. The skin integrity and barrier function
are tightly regulated by a complex network of cell–cell and
cell–matrix interactions. In particular, the cellular regeneration of
skin epidermis and hair follicles is maintained along lifespan of individuals by different adult stem/progenitor cell subpopulations localized within the specialized microenvironments, niches in basal layer
of epidermis, sebaceous gland and hair follicle bulge region (Fig. 1)
[7–20]. These small subpopulations of immature cells endowed
with a high self-renewal capacity and multilineage differentiation
ability contribute to replenish the different skin cell lineages, including mature and specialized keratinocytes, sebocytes or
melanocytes, in homeostatic conditions or after intense skin
injuries. A chronic or cumulative ultraviolet-light (UV) exposure and
inflammation of skin and oxidative stress and telomere shortening
in skin stem/progenitor cells and their progenies, however, usually
lead to their dysfunctions or loss via the senescence or apoptotic
death with advancing age (Figs 1 and 2) [21–28]. This age-related
decline in skin regenerative cells may result in a skin homeostatic
imbalance and severe cutaneous disorders [23–28]. In particular, a
long-term exposure of skin cells to environmental insults such as
UV radiations and internal metabolic reactions typically generates
highly toxic products and reactive free radicals [1, 3, 21, 23, 25–27,
29, 30]. These molecular events may cause severe damages to
mitochondrial and nuclear DNA, membranes, lipids and proteins in
skin-resident stem/progenitor cells and their progenies as well as
dermal fibroblasts, and ultimately lead to cell dysfunctions or loss
during chronological aging. Of therapeutic interest, numerous therapeutic approaches have been developed to restore the skin
integrity and functions with advancing age and improve the repair
mechanisms after severe injuries. The use of antioxidants, antiinflammatory and detoxifying agents, calorie restriction and stem
cell-based therapies have emerged as the promising strategies to
prevent or delay the functional decline or loss of skin-resident adult
stem/progenitor cells and their progenies occurring during chronological aging or photoaging [25, 28, 31–43]. These anti-aging
strategies, which may improve the stress resistance and survival of
skin regenerative cells, represent the potential therapies to prevent
the age-related skin detrimental alterations and disorders such as
premature aging diseases, chronic non-healing wounds and ulcers
and ectodermal dysplasia [25, 28, 31–43].
In addition, the photoaging and accumulation of genetic and/or
epigenetic alterations in skin stem/progenitor cells and their progenies as well as their microenvironment, including age-related
changes in the expression levels of numerous gene products, may
lead to development of cutaneous basal cell and squamous cell
cancers (BCCs and SCCs) or aggressive and recurrent melanoma
(Fig. 1) [1, 4, 6, 13, 22, 28, 44–52]. More specifically, telomere
attrition, the gene mutations leading to inactivation of diverse

tumour suppressor gene products [p16INK4A, p19ARF, retinoblastoma (pRb) and/or p53] combined with a sustained stimulation of
diverse developmental signalling cascades initiated by distinct
growth factors, and defects in DNA repair mechanisms may contribute to skin cancer initiation and progression (Figs 2 and 3)
[1, 6, 13, 28, 44–55]. Among the growth factor cascades that are
often deregulated in skin cancer stem/progenitor cells and their
progenies, there are hedgehog, epidermal growth factor receptor
(EGFR), Wingless (Wnt)/b-catenin, Notch, Nodal/Cripto-1, extracellular matrix (ECM)/integrins and/or Polycomb group protein
BIM-1 signalling pathways (Fig. 3). In support with the critical
functions of skin cancer stem/progenitor cells in the skin cancer
development and metastases, small subpopulations of highly
tumorigenic cancer cells with stem cell-like properties have been
identified in situ and isolated from BCCs, SCCs and primary and
secondary melanoma tumours and established skin cancer cell
lines [44, 56–66]. In addition, the development of skin cancers is
generally accompanied by extensive changes in the local microenvironment of skin cancer stem/progenitor cells and their progenies
including in their niches and ECM components as well as the secretion of diverse paracrine mitotic factors by activated stromal cells
that contribute to their acquisition of a more malignant behaviour
(Fig. 1) [1, 2, 28, 67–69]. Therefore, the molecular targeting of
distinct deregulated oncogenic products in skin cancer stem/
progenitor cells and their microenvironment offers great promise
to eradicate the total cancer cell mass including skin cancerinitiating cells and their progenies, and thereby improve the current
cancer therapies.
In this article, we reviewed the specific functions provided by
each adult stem/progenitor cell type in skin maintenance and regeneration as well as their potential implications in the development
of age-related skin disorders and cancers. The emphasis is on the
molecular and cellular mechanisms associated with dysfunctions
or loss of skin-resident adult stem/progenitor cells and their progenies during chronological aging as well as new anti-aging and
cancer therapies to treat a diversity of severe skin disorders and
aggressive cancers.

Functions of skin-resident adult stem/
progenitor cells in skin regeneration
The cellular regeneration of the skin is maintained by different
adult stem/progenitor cell subpopulations localized within the specialized microenvironments, niches in interfollicular epidermis
(IFE), sebaceous gland and hair follicle bulge region (Fig. 1)
[7–20, 70–72]. The epidermal barrier is affected by a continuous
loss of terminally differentiated keratinocytes in the outermost epidermal layer, the stratum corneum that are shed from the skin surface during the desquamation process [1, 6]. The small clusters of
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Fig. 1 Scheme showing the anatomical localization of skin-resident adult stem/progenitor cell niches and the potential cellular changes associated with
the skin aging and cancers. The small pool of KSCs resident in basal layer of the epithelial compartment are able to regenerate the skin stratified epithelium by replenishing all of the differentiated epithelial keratinocytes, including terminally differentiated keratinocytes at the skin surface lost during desquamation process. Moreover, bESCs in the follicle hair may also replenish the keratinocytes constituting of appendages including sebeceous gland and interfollicular epithelium during the hair growth cycle and tissue regeneration after severe skin injury. Additionally, the bulge-resident melanocyte stem cells
may generate the melanocyte precursors that can migrate via ORS to the germinal matrix at the bulg areas of each hair follicle, and thereby replenish the
mature pigmented melanocytes that are responsible for the hair pigmentation by transferring melanin to keratinocytes. This scheme also shows the potential consequences of the chronological aging of skin stem/progenitor cells including the wrinkles and hair growth defects leading a decreased hair pigmentation (greying) and loss. Moreover, the skin cancers including basal cell and squamous cell carcinomas and melanoma which may derive from
genetic alterations in KSCs, bESCs or melanocyte stem cells are indicated. The degradation of collagen in dermal layer through the release of MMPs by
the activated or senescent dermal fibroblasts which may promote the development of skin disorders and invasive cancer subtype is also illustrated.

undifferentiated and unipotent keratinocyte stem cells (KSCs) with
stem cell-like properties and expressing cytokeratins (CK5/14/15),
p63, a6b4- and a3b1-integrins, and ATP-binding cassette (ABC)
transporters, have been identified near basement membrane in the
basal layer of epithelial compartment (Fig. 1) [2, 7, 8, 10, 11, 13,
70, 73]. KSCs provide critical roles in participating to the continuous replenishment of mature keratinocytes of epidermis in homeostatic conditions and after skin injuries [7, 11, 13, 14]. A complex
network of signalling cascades such as EGFR, Notch, insulin-like
growth factor (IGF-1)/IGF-R1, immunoglobulin-like domains 1
(Lrig1), Myc, transforming growth factor-b (TGF-b) and
Polycomb-group protein BMI-1 is involved in the stringent regulation of KSCs behaviour [6, 8–11, 70, 74–79]. The integration of
these diverse signalling pathways in KSCs may result in their proliferation and/or differentiation into keratinocytes during skin tissue regeneration. In this regard, an asymmetric division of KSCs
generates the transit amplifying (TA)/intermediate cells [80]. TA
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cells in turn migrate outside the niche and give rise to the intermediate keratinocytes and more committed terminally differentiated
keratinocytes constituting various epidermal layers of the skin
[80]. The down-regulation of EGFR in KSCs concomitant with an
enhanced activity of p53 and expression of its targets Notch1 and
p21WAF1/CIP1 may notably promote the keratinocyte differentiation
[81–83]. Moreover, other signalling effectors, including inhibitor
of kB (IkB) kinase-a (IKK-a), interferon regulatory factor 6 (IRF6)
and cell cycle regulator protein stratifin (SFN, also designated as
14–3-3s protein) also provide critical functions in the regulatory
processes controlling keratinocyte proliferation-differentiation
switch from a mitotic state to a terminally differentiated state [73,
84–89]. Additional studies are however necessary to establish the
precise roles of IRF6, IKK-a and SFN in KSC behaviour versus
their differentiated progenies.
In addition, a small subset of unipotent progenitor cells
expressing CK5/14 and B-lymphocyte-induced maturation protein
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Fig. 2 Schematic representation of possible molecular events associated with the dysfunctions or loss of skin-resident stem/progenitor cells. This
scheme suggests that telomere shortening, mutations, DNA repair defects and/or a long-term ultraviolet (UV) exposure of skin-resident stem/progenitor
cells during chronological aging may be accompanied by a decline of their functions or loss. Particularly, the alterations in the growth factor signalling
pathways involved in the stringent control of the self-renewal capacity of these immature cells may lead to their dysfunction. Moreover, the enhanced
expression levels and activation of the p16INK4A/retinoblastoma (Rb) and p19ARF/p53 cascades may result in an inhibition of CDK/cyclin complexes, inactivation of the E2F transcription factor and growth arrest or senescence. In addition, p53-induced pro-apoptotic factors including Bax, may also trigger
the apoptotic death of these skin regenerative cells with advancing age. In addition, this scheme also specifies that the tumour-suppressing effect mediated through the p16INK4A- and/or p53-initaited pathways may counteract the malignant transformation of skin cancer-initiating cells. Alternatively, the
telomerase activation combined with the occurrence of distinct genetic and/or epigenetic alterations leading to inactivation of tumour suppressor genes
and sustained activation of diverse developmental pathways in skin stem/progenitor cells may culminate in their malignant transformation into skin
cancer stem/progenitor cells and skin tumour formation.

1 (BLIMP1) has also been identified near basement membrane
surrounding the cutaneous sebaceous gland in the hair follicle
(Fig. 1) [17]. These skin progenitor cells contribute to regenerate
the sebaceous gland including the terminally differentiated sebocytes that provide important functions in the endocrine and hormonal regulation of skin integrity and sebum secretion [5, 17].
Moreover, the multipotent epithelial stem cells (bESCs) expressing
different markers such as CK5/14/15/19, CD200, p63, a6b4- and
a3b1-integrins have been identified in the bulge niche of the hair
follicle (Fig. 1) [8, 9, 12, 15, 16, 22, 71, 90–93]. It has also been
reported that murine bESC may be distinguished from KSCs on

the basis of their CD34 expression while the CD34 marker is not
expressed by human bESCs in bulge niche [12, 71, 94, 95]. A
human CD341 subpopulation resident in upper region of the outer
root sheath (ORS) of the hair follicle, however, has been observed
to more effectively regenerate new hair follicle in immunodeficient
nude mouse than CD342 cells suggesting that a large niche could
be occupied by human ESCs [96]. bESCs or early progenies serve
as a source of immature cells to regenerate the epidermal cells
in skin appendages or damaged epithelial tissue in response
to intense injuries (Fig. 1) [2, 7–9, 12–16, 22, 71, 92–94]. Indeed,
the hair follicles typically undergo repeated growth cycles consisting
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Fig. 3 Scheme showing the potential oncogenic cascades involved in the malignant and aggressive phenotypes of melanoma stem/progenitor cells. The
intracellular signalling cascades induced through the activation of distinct growth factor pathways which may provide a critical role for the sustained
growth, survival, migration, invasion, metastases and/or drug resistance of melanoma stem/progenitor cells, are shown. These tumorigenic cascades
include sonic hedgehog SHH/PTCH (patched receptor)/GLI, Cripto-Nodal-ALK4/7/ActRIIB activin-like kinases receptor complex, CD133 pentaspan
transmembrane protein, Notch/Ligand (Delta and Jagged), hyaluronan (HA)/CD44 and Wnt/Frizzled (Fzd)/b-catenin. The up-regulated expression levels
of certain target gene products including up-regulated cyclin D1, c-Myc, Bcl-2, Nodal, N-cadherin, matrix metalloproteinase (MMPs), urokinase plasminogen (uPA), cyclooxygenase (COX-2) and vascular epidermal growth factor (VEGF) that can contribute to the malignant transformation of melanoma
stem/progenitor cells are also indicated. In addition, the potential molecular targeting strategies by using a selective inhibitor of SMO hedgehog signalling element (cyclopamine), Nodal (Lefty), EGFR (gefitinib or erlotinib), g-secretase and monoclonal antibody (mAb) directed against Cripto-1, CD133
and ABC multidrug transporter.

to the periods of active growth (anagen), regression (catagen) and
rest (telogen). During the hair cycle, the activation of quiescent
bESC subpopulation leads to their division and generation of TA
cells that in turn can leave the bulge niche and migrate along the
ORS forming the outermost layer toward germinal matrix and dermal papilla where they can give rise to mature keratinocytes (Fig.
1). In this matter, it has been reported that the induction of telomerase or its catalytic subunit, telomerase reverse transcriptase
(TERT) in mouse skin epithelium caused a rapid transition from
the resting phase of hair follicle cycle (telogen) into the active
phase (anagen) by activating hair follicle stem cell proliferation
[97–100]. In fact, TERT may directly promote the entrance of
120

quiescent hair follicle stem/progenitor cells into the cell cycle by
modulating the Wnt and Myc pathways [98–101]. The interplay of
a complex network of several developmental signalling cascades
initiated by different growth factors as well as the changes in key
niche components generally participate to the stringent regulation
of bESC behaviour during hair follicle growth and/or IFE regeneration after severe injuries [13, 15, 22, 71, 93, 102–106]. These
pathways include sonic hedgehog (SHH/PTCH/GLI), EGFR,
Wnt/b-catenin, Notch, nuclear factor-kappa B (NF-kB), bone morphogenic protein (BMP), BMI-1 and SOX9 transcription factor.
Particularly, the activation of Wnt/b-catenin pathway seems to be
necessary for the fate specification of bESCs into hair follicular
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keratinocytes rather IFE keratinocytes during hair growth cycle
while Notch signalling may contribute to the maintenance of the
hair follicle fate of bESCs [103, 107–110].
The lower permanent portion of the hair follicle bulge region in
human and mice also contains a small subpopulation of immature
melanocyte stem cells with stem cell-like properties that can give
rise to melanocyte precursors and mature melanocytes in bulb
areas at the base of hair follicle (Fig. 1) [18, 21, 111–115]. The gene
expression analyses of melanocyte stem cells isolated from murine
hair follicles revealed that they express dopachrome tautomerase
(Dct) and paired-box transcription factor PAX3 like melanocytes
[111, 115]. The undifferentiated melanocyte stem cells, however,
may be distinguished from melanocyte precursors and mature
melanocytes by a down-regulated expression of melanocyte-specific gene products such as microphtalmia-associated transcription
factor (MITF), SRY (sex determining region Y)-box 10, SOX10 transcription factor, lymphoid enhancer-binding factor 1(LEF1), KIT and
tyrosinase-related protein 1 (Tyrp1) [111, 115]. More specifically,
during the anagen phase of hair follicle cycle, activated melanocyte
stem cells in the hair follicle bulge region generate the melanocyte
precursors that migrate along the ORS to regenerate the epidermal
and hair matrix melanocytes (Fig. 1) [18, 21, 112]. The differentiated
and pigmented melanocytes localized at the base of each hair follicle in the bulb areas provide critical functions in hair pigmentation
by producing the specialized melanin-containing vesicles,
melanosomes that are transferred to neighbouring keratinocytes.
Numerous signalling pathways are involved in the stringent regulation of the maintenance of bulge-resident melanocyte stem cells in
quiescent versus activated states as well as in their survival, proliferation, migration and differentiation into melanocyte lineage [18,
21, 113–123]. These signalling elements include Notch1 and 2,
stem cell factor (SCF)/KIT, stromal cell-derived factor-1 (SDF1)/CXC chemokine receptor 4 (CXCR4), PAX3, MITF and anti-apoptotic factor, Bcl-2 [18, 21, 113–123].
In addition, different cell types, which may derive from
pluripotent neural crest stem cells during embryonic development, may also be generated from bulge-resident stem cells or
their progenitors in post-natal life in adult mammifers [19, 20,
113, 124–132]. More particularly, the bulge area in human hair
follicle contains a small subpopulation of pluripotent epidermal
neural crest stem cells (eNCSCs) expressing stem cell-like markers such as nestin, SOX9, Nanog and Oct-3/4 that can give rise to
multiple skin cell lineages including melanocytes, neurons and
smooth muscle cells [20]. Another subpopulation of multipotent
adult skin-derived precursors (SKPs), which reside within the
dermal papillae of hair follicles, also appear to exhibit properties
similar to those of eNCSCs [129, 130, 133]. SKPs can be
expanded in the presence of EGF, basic fibroblast growth factor
(bFGF) and TGF-b and give rise to neurons, glia, smooth muscle
cells, and adipocytes in culture in vitro. Additionally, it has also
been reported that the multipotent human skin-derived CD1331
cells expressing the CD34 and Thy-1 antigens were able to proliferate in the presence of EGF and bFGF, form spheres, and differentiate into neurons, astrocytes, and rarely into oligodendrocytes
in vitro as well as astrocytes and endothelium in vivo [134].

Future investigations are however necessary to establish the hierarchical organization of these skin-resident stem/progenitor cells,
and more particularly, to determine whether bulge-resident
melanocyte stem cells or SKPs may arise from more primitive
eNCSCs as well as their specific functions in skin maintenance
and cell regeneration after severe injuries.
On the other hand, the stromal cells including fibroblasts and
dermal sheath cells (DSCs) as well as multipotent dermal-resident
mesenchymal stem cells (MSCs) and endothelial progenitor cells
(EPCs) have been detected in human dermis and vascular well of
skin tissue, respectively [78, 135–137]. Hence, these skin cells
can participate to skin regeneration and cutaneous wound healing
through the release of diverse paracrine factors. More specifically,
the differentiation of EPCs into mature endothelial cells may contribute to the formation of new vessels after severe skin injuries.
Similarly, bone marrow (BM)-derived MSCs and EPCs can also
migrate to severe injured cutaneous tissues such as non-healing
chronic wounds, and thereby take part to skin repair and regeneration processes [135, 138, 139].
Collectively, these observations suggest that the interplay of
different types of skin-resident adult stem/progenitor cells
contribute to the maintenance of skin integrity and functions in
homeostatic conditions and during tissue repair after severe
injuries. Unfortunately, the dysfunctions, loss or malignant
transformation of these rare regenerative skin-resident
stem/progenitor cells during chronological aging or in pathological conditions may result in the development of severe skin
disorders and cancers.

Altered functions of skin-resident
adult stem/progenitor cells during
chronological aging
The structural integrity and functions of skin are generally
altered with passage of time [1, 3, 21, 25]. The chronological
intrinsic aging of skin cells may result in a progressive
decrease of turnover epidermal time and loss of tone and elasticity of skin [1, 3, 21, 25, 140]. Moreover, the skin aging is
also accompanied by an increased susceptibility to injury and
infection, epidermal dehydratation, reduced wound healing,
wrinkles (rhytides), pigmentary alterations, hair greying and
loss, blood vessels weakness, and increased risk of skin
epithelial cancers and melanoma (Fig. 1) [1, 3, 21, 25–27,
140]. Among the principal environmental factors that may promote the skin-aging process and ultimately carcinogenesis, a
repeated exposure to solar UV radiations is critical [25, 27, 48,
49, 54, 141]. Although the active repair mechanisms and
melanin synthesis may protect the skin cells against UV radiation-induced cellular damages, a chronic or cumulative exposure to sunlight may induce several gene mutations and
culminate to development of skin disorders such as epidermal
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atrophy, psoriasis, keratosis, depigmentation and dysplasia as
well as skin cancer initiation.

Potential implications of skin-resident stem/
progenitor cells in skin aging-related disorders
Accumulating lines of experimental evidence have revealed that
the chronological or premature aging of skin may be associated
with dysfunctions or loss of certain skin-resident stem/progenitor
cells (Figs 1 and 2) [24, 26–28, 97]. This decline in the functional
properties or number of KSCs and bESCs with the time may impair
the skin regeneration process and wound healing, and contribute
to development of diverse skin disorders [10, 24, 26, 27, 97]. For
instance, the results from a study carried out using the sunexposed and sun-protected skin samples obtained from old individuals revealed that the KSC number was lower in photoaged skin
than in chronologically aged skin specimens [27]. Moreover, it has
been reported that the telomere shortening may occur in hair follicle stem cells with aging, and thereby lead to DNA instability and
a decline in their functional properties including their capacity to
replenish mature and functional keratinocytes and melanocytes of
follicle during the hair growth cycle [97].
The chronological aging and photoaging of skin is also accompanied by an extensive ECM remodelling in dermal layers such as
the occurrence of EMT program or senescence of skin fibroblasts,
dramatic up-regulation of matrix metalloproteinases (MMPs) and
a decrease of collagen production (Fig. 1) [140, 142, 143].
Particularly, the fibroblasts in aged skin can produce high levels of
matrix MMPs and low levels of collagen [142]. An exposure of
human skin fibroblasts to UV irradiation may also result in oxidative stress and enhanced expression of p16INK4A and
p53/p21WAF1/CIP1-induced fibroblast premature senescence and/or
the activation of the fibroblast to myofibroblast transition [29, 69,
143, 144]. These molecular events may lead to a loss of skin tone
and elasticity, fibrosis and increased risk to develop aggressive
and invasive skin cancers such as melanoma and morphoeic BCC
subtype, which is characterized by an infiltrative growth pattern
and densely fibrous stroma as compared to the most low-risk and
indolent BCCs [29, 68, 69, 144].
In addition, diverse premature aging disorders, which are
typically caused by inherited or sporadic genetic mutations in
key gene products resulting in detrimental nuclear lamina alterations, an accelerated telomere attrition and/or DNA repair
defects, are also associated with an accelerated apparition of
skin aging phenotypes and premature death of patients
[145–152]. The premature aging disorders include HutchinsonGilford progeria syndrome, Werner syndrome, dyskeratosis congenital, ataxia-telangiectasia, Fanconi anaemia, aplastic anaemia,
xeroderma pigmentosum (XP), Cockayne syndrome and trichothiodystrophy [145–153]. In general, the genetic abnormalities associated with these diseases may lead to genomic instability and dysfunctions in adult stem/progenitor cells and their
progenies in diverse tissues including skin. Hence, these accel-
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erated aging disorders may be accompanied by a premature loss
of hair and subcutaneous fat, hair greying, severe skin atrophy
and/or an enhanced propensity to develop diverse diseases
including skin disorders and cancers [28, 148–161]. In this
regard, several animal models have been developed to establish
the cellular and molecular events that may promote the aging
process and skin disorder development.

Animal models of skin-resident stem/progenitor
cell aging and disorders
Several studies carried out on mice models have indicated the
potential implication of the senescence or apoptotic death of
skin-resident adult stem/progenitor cells and their progenies in
acquisition of certain premature aging phenotypes and the
pathophysiological development of age-related skin disorders
[21, 97, 116, 119, 152, 162]. For instance, it has been observed
that the telomerase-deficient TERC–/– mice with critically short
telomeres, which possess dysfunctional bESCs showing a
reduced ability to be mobilized out of their niche and an impaired
capacity to regenerate the hair follicle and skin epidermis, were
characterized by a premature skin-aging and death [98]. In fact,
bESCs isolated from these telomerase-deficient mice exhibited a
low proliferative capacity ex vivo [98]. Interestingly, the TERT
re-introduction into late-generation telomerase-deficient TERC–/–
mice, however, could restore the telomerase activity and
telomere length and prevent bESC defects and premature skin
pathologies associated with aging and death of mice without
increased the tumorigenesis [98, 163]. In the same pathway, it
has also been reported that the number and proliferative capacity of bESCs were decreased in Zmpste24-null progeroid mice,
which display progeroid symptoms characterized by an aberrant
nuclear envelope architecture due to nuclear lamina defects, as
compared to Zmpste24–/– Lmna1/2 mutant mice [164]. It has
also been noticed that Wnt and MITF were altered in dysfunctional bESCs and these immature cells and their supporting cells
in the hair bulb region showed an enhanced rate of apoptotic
death [164]. The p531/m or DNp63a mice, which display the
pathological signs associated with premature skin aging-related
phenotypes, were also characterized by a decreased expression
level of nicotinamide adenine dinucleotide (NAD)-dependent
deacytylase protein, sirtuin 1 (SIRT1, silent mating type information regulation 2, homologue 1), and reduced longevity relative
to wild-type animal [165]. Importantly, an inhibition or conditional ablation of Notch/Hes1, Bcl-2-dependent SCF/KIT and
master regulator MITF signalling elements also caused a gradual
and dramatic elimination of bulge-resident melanocyte
stem/progenitor cells by apoptosis in animal model in vivo [21,
112, 118–120, 126, 166]. This progressive loss of melanocyte
stem/progenitor cells and their mature progenies, the melaninproducing melanocytes in the bulb areas, was accompanied by a
severe defect in hair pigmentation and an accelerated and intensive hair greying, the prototypical signs of skin aging (Fig. 1)

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 14, No 1-2, 2010
[21, 118–120, 166]. Of particular interest, the hair greying phenotype and premature mice death by polycystic kidney disease
observed for Bcl-22/2 mice could be prevented by a simultaneous down-regulation of pro-apoptotic BH3-only Bcl-2 family
member, BIM suggesting that this factor may constitute a potential anti-aging therapeutic target [166].
In addition, certain lines of experimental evidence have also
indicated that the activation of p16INK4A/pRb and/or p53 tumour
suppressor-induced signalling pathways, which may lead to cellular senescence or apoptotic death, may contribute to counteract
skin cancer development (Fig. 2) [28, 167–171]. As a matter of
fact, the presence of functional p53 signalling pathway in TERC2/–
mice, which are deficient in telomerase, has been associated with
an induction of senescence and apoptotic cell death and enhanced
resistant to spontaneous skin tumorigenesis [170, 171]. However,
TERC2/– p53R172P mice, which are able to trigger the senescence
via the p53/ p21CIP1/WAP1 cascade but not apoptosis were resistant
to spontaneous skin tumorigenesis while skin carcinomas were
induced by 7, 12-dimethylbenz[a]anthracene (DMBA) plus 12-Otetradecanoylphorbol-13-acetate (TPA) in these mice [171]. In
fact, five out of seven chemically treated TERC2/– p53R172P mice
developed highly proliferative pre-malignant lesions, squamous
papillous/keratoacanthomas and four out of five mice displayed
invasive SCCs despite a high staining of p53/p21CIP1/WAP1 were
detected in these malignant lesions [171]. In the same way, it
has been observed that the K5TRF2 mice overexpressing telomere-binding factor 2 (TRF2) under control of the regulatory
region of keratin 5 (K5) gene in the stem cell compartment of different epithelia including the skin, exhibited severe premature
skin aging defects with increased age as compared to agematched wild-type mice [152, 172]. These skin defects of
K5TRF2 mice include hair loss, skin hyperpigmentation and dryness and an increased predisposition to develop skin cancer
after exposure to light [152, 172]. These skin defects, which
resemble to the skin phenotypes observed in some human premature aging disorders such as XP syndrome, have been associated with a XPF nuclease-dependent telomere loss and
increased chromosomal instability induced through an enhanced
expression of TRF2 and p53 in bESCs leading to their dysfunction [152]. Importantly, p53 deletion in K5TRF2 mice model
could rescue bESC defects in the absence of telomere elongation
while these K5TRF2/p532/– mice showed an accelerated onset of
pre-neoplastic skin lesions and UV-induced skin carcinogenesis
including BCCs and SCCs relative to K5TRF2, p532/– and/or
wild-type mice used as controls [152].
Altogether, these observations suggest that the induction of
cell cycle arrest and senescence mediated through the stimulation
of tumour suppressor gene products such as p53 may be effective
to decrease the incidence of only certain skin cancer subtypes.
Moreover, the down-regulation of tumour suppressor gene products combined with an accumulation of numerous genetic and/or
epigenetic alterations in skin-resident stem/progenitor cells during
chronological aging or photoaging may also allow them to bypass
the senescence and apoptotic cell death processes and culminate
to skin cancer development.

Altered functions of skin-resident adult
stem/progenitor cells in skin hyperproliferative disorders and cancers
The down-regulation of tumour suppressor gene products such
as p16INK4A/pRb, p19ARF/p53/p21WAPI/CIPI and/or phosphatase
and tensin homologue deleted on chromosome 10 (PTEN),
deregulation of growth factor signalling cascades involved in the
stringent regulation of proliferation, survival and/or differentiation of KSCs and bulge stem cells and photoaging represent
important factors that contribute to development of diverse skin
pathologies (Figs 1 and 2) [6, 51, 55, 83, 173–176]. Among
them, there are the epidermal hyperproliferative disorders such
as impaired wound healing and psoriasis, basaloid follicular
hamartoma and skin cancers including BCCs, SCCs and
melanoma. Particularly, a long-term skin exposure to UV radiations may cause inflammatory and immunosuppressive effects
and DNA damages on sun-exposed areas of skin, and thereby
result in major DNA mutations and photoproduct formation in
skin cells promoting skin cancer initiation [25, 48–50, 52, 162,
177]. For instance, a depletion of cellular antioxidant enzymes
such as catalase and superoxide dismutase (SOD) induced
through an UV light exposure may result in an enhanced reactive
oxygen species (ROS) production and oxidative stress [25, 30].
These molecular events may cause severe damages to DNA, proteins, lipids and carbohydrates in skin cells, and thereby promote
skin cancer development. In this matter, we are reporting frequent deregulation occurring in skin-resident adult
stem/progenitor cells and their progenies which may be associated with the development of BCCs, SCCs or melanoma.

Potential implications of cancer stem/progenitor
cells in basal cell and squamous cell cancers
Recent studies revealed that an extensive UV light exposureinduced DNA mutations and genetic and/or epigenetic alterations
leading to a sustained activation of TERT, hedgehog, EGFR
and/or Wnt/b-catenin signalling pathways in skin-resident
stem/progenitor cells and their progenies contribute to the
development of certain cutaneous BCC and SCC subtypes [1, 49,
52, 83, 173, 178]. In this regard, accumulating lines of experimental evidence have indicated that certain subtypes of BCCs
and SCCs could derive from the malignant transformation either
of skin bESCs or their early progenies localized within or in close
proximity to the bulge niche in hair follicles and/or skin cells in
the basal layer of IFE [44, 47, 56, 57, 175, 179, 180]. More particularly, a sustained activation of sonic hedgehog pathway
SHH/patched (PTCH)/GLI transcription factors, due to an overexpression of SHH ligand, activating mutations in smoothened
(SMO) co-receptor or inactivating mutations in PTCH receptor as
well as Wnt/b-catenin cascade in skin cells has been associated
with the etiopathogenesis of certain inherited or sporadic BCC
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subtypes in human [49, 102, 180–184]. Consistent with critical
implication of hedgehog cascade in BCCs, it has been shown that
an aberrant expression or activation of hedgehog signalling effectors, including the overexpression of SHH ligand, an activated
human M2SMO mutant or GLI-1 or 2, in skin stem/progenitor
cells found in hair follicles and/or basal layer of epidermis in mice
model in vivo resulted in the cell hyperproliferation and human
BCC-like tumour development [56, 175, 185–192]. Moreover,
it has been observed that the SOX9 transcription factor, which
represents a potential downstream target of hedgehog pathway
in hair follicle bESCs, was strongly expressed in cancer cells
detected in BCCs [179]. The ablation of Notch1 receptor in mouse
epidermis by using tissue-specific inducible gene-targeting
approach also resulted in a sustained expression of GLI-2 concomitant with the development of epidermal hyperplasia followed
by BCC-like tumours [193]. These data suggest then that Notch1
may act as a tumour-suppressor gene product in skin epidermis.
In this matter, loss-of-function mutations in PTCH-1 receptor or
activating mutations in SMO resulting in a constitutive activation
of hedgehog pathway, has also been associated with the development of rare diseases such as nevoid basal cell carcinoma
syndrome (NBCCS) and accelerated aging disorder, XP, which
are typically characterized by skin defects and a high BCC
incidence [159–161, 183, 186, 194].
On the other hand, an increased expression of CK19, which is
considered as a putative marker of bESCs, has also been
observed in certain SCC tissue specimens [44]. Moreover, a
small subpopulation of murine CD341 cancer stem/progenitor
cell population characterized by the phenotypic and functional
properties like normal bESCs has been detected in early stage of
SCCs [57]. The isolated fraction of CD341 cancer stem/
progenitor cells were able to give rise to the tumours after transplantation in mice in vivo showing a hierarchical organization
resembling primary malignant neoplasm [57]. The ablation of
1
the b-catenin gene in these CD34 cancer stem/progenitor cells
resulted in their loss and a complete tumour regression suggesting a critical role of the activation of Wnt/b-catenin cascade in
triggering of certain SCC subtypes [57]. The transcriptional
suppression of p53 induced-Notch gene expression through the
activation of EGFR/c-Jun signalling in keratinocytes also led to a
down-regulation of Notch1-initiated differentiation pathway
and expansion of stem cell populations that promoted the development of SCCs [82, 83]. In spite these advances, additional
investigations are necessary to more precisely determine the
specific implication of KSCs residing near the basement membrane in basal epithelial layer versus bESCs in the development
of different BCC or SCC subtypes (Fig. 1).

Potential implications of cancer stem/progenitor
cells in melanoma
A growing body of experimental evidence has also revealed that
the cutaneous melanoma, which generally shows a high propen-
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sity to metastasize and resistance to current therapeutic treatments, could arise from cancer cells endowed with stem cell-like
properties [58–63, 112, 195–198]. In support with this, small
subpopulations of cancer stem/progenitor cells with stem cell-like
properties have been identified and isolated from primary and secondary tumour specimens of patients with melanoma as well as
human primary WM115 and metastatic WM239A and murine
B16F10 melanoma cell lines [58–63, 65, 195, 196, 198]. These
melanoma stem/progenitor cells expressed different biomarkers
[CD133, CD44, CD20, telomerase reverse transcriptase (TERT),
nestin, Nanog and/or ABC transporters such as MDR-1, ABCG2
and ABCB5]. More specifically, it has been reported that a small
subset of cancer stem/progenitor cells expressing MDR1/ABCB2/ABCB5/Nanog/TERT markers, which has been isolated
from primary melanoma specimens, showed higher clonogenicity
and self-renewal capacities in vitro than MDR-1 negative cancer
1
cell fraction [62]. The ex vivo culture of a CD20 cancer cell fraction enriched from melanoma cell lines and metastases in the
growth medium, which is used for human embryonic stem cells,
also resulted in their propagation under form of non-adherent
spheres [59]. Each individual multipotent CD201 cancer cell from
melanoma spheres was able to differentiate like eNCSCs into multiple cell types showing the phenotypic features like the
melanocytes, adipocytes, osteocytes and chondrocytes under well
definite culture conditions [59]. Moreover, the CD1331 melanoma
cells isolated from metastatic melanoma biopsies were also able
2
to form melanocytic tumours in mice in vivo while the CD133
cancer cell fraction does not induce the melanoma formation [61].
In the same way, a small subpopulation of Cripto-11 cells
expressing elevated levels of Oct3/4, Nanog and MDR-1 stem celllike markers, which has been isolated from the metastatic
melanoma cell line C8161, also displayed a slow growing and
sphere forming capacity in vitro [199]. Another small side population (SP) expressing nestin and premelanosomal marker, gp100
has also been isolated by efflux Hoechst 33342 dye technique
from metastatic melanoma DM1N, DM2N and DM3N cell lines
which were originally established from lymph node melanoma
metastases. It has been observed that these SP cells, which possessed a small size and were less melanized that other cell fraction, were able to give rise to differentiated melanoma cells. These
SP cells also showed a high resistant to cytosine b-D-arabinofuranoside hydrochloride (Ara-C) treatment [64]. Hence, it appears
that the primary and metastatic melanomas may arise from
tumorigenic cancer cells with the stem cell-like properties.
Particularly, the transition from skin-confined melanoma into invasive and metastatic melanocytic tumours usually implicates an
accumulation of distinct oncogenic events in tumorigenic
melanoma cells.

Molecular events associated with melanoma progression
The progression of primary melanoma into aggressive, invasive
and metastatic melanocytic tumours is usually associated with
a deregulation in numerous signalling elements. Among them,
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there are the alterations in tumour suppressing pathways
INK4A
/cyclin-dependent kinase 4 (CDK4)/pRb and
including p16
ARF
p19 /p53 as well as the activation of multiple growth factor
cascades such as hedgehog, Wnt, Notch, Nodal and diverse
receptor tyrosine kinases (RTKs) such as EGF/EGFR, SCF/KIT
and hepatocyte growth factor/scatter factor (HGF)/c-MET and
activating mutations in KIT (Fig. 3) [46, 53, 66, 174, 200–204].
Particularly, inherited or somatic events including an inactivation of tumour suppressor genes such as p16INK4A, p19ARF, p53
and PTEN and/or activating mutations in KIT, H-Ras, N-Ras or
B-Raf (v-Raf murine sarcoma viral oncogene homologue B1)
combined with a sustained activation of diverse signalling elements including Ras/ERK, PI3K/Akt and NF-kB generally contribute to melanoma development (Figs 2 and 3) [55, 177, 201,
205–210]. For instance, the data from an investigation consisting of a 10-year follow-up period of 31 patients with melanoma
have revealed that a decreased expression of pRb, p53,
p21WAF1/CIP1, p27KIP1 and pro-apoptotic factors, Bax and Bak
may be associated with a higher risk of melanoma metastases
[55]. In support with critical functions of p16INK4A and p19ARF
protein loss and Ras activation in the development of aggressive metastatic melanomas, it has been observed that the
majority of Tyr::N-RasQ61K INK4A2/– transgenic mice developed
primary melanocytic and multifocal tumours that metastazed to
lymph nodes, lung and liver [66]. The cancer cells expressing
the stem cell-like marker, nestin isolated from primary
melanoma specimen could also be subcutaneously transplanted
in nude mice, and when intravenously injected into non-obese
diabetic-severe combined immunodeficiency (NOD/SCID) mice,
they metastazed at lung [66]. Interestingly, recent data have
also revealed that the stem cell-like markers including CD133,
CD44 and ABCB5 multidrug transporter, which are expressed by
melanoma stem/progenitor cells, can contribute to their malignant behaviour, and thereby they could constitute the potential
molecular therapeutic targets (Fig. 3) [63, 65, 195]. In this matter, it is worth mentioning that the phenotypic and functional
features of melanoma stem/progenitor cells as well as the number of melanoma-initiating cells that are able to drive tumour
development may vary during the disease progression and
before and after treatment initiation. As a matter of fact, a high
proportion of human melanoma cells isolated from patients with
primary and metastatic melanomas and expressing different
phenotypic markers were able to form tumours in highly
immunocompromised mice models in vivo [211]. Therefore,
future investigations are required to more precisely definite the
gene expression profiles and functions of specific stem cell-like
markers expressed by melanoma stem/progenitor cells versus
their differentiated progenies in the primary and secondary
melanocytic tumours during cancer etiology and progression.
Particularly, it will be important to establish if melanoma-initiating cells may derive from the malignant transformation of
bulge-resident stem/progenitor cells like eNCSCs, melanocyte
stem cells and/or their early progenitors endowed with the stem
cell-like properties. These studies should help to develop effec-

tive multitargeted therapies for eradicating the total mass of
melanoma-initiating cells and their progenies at early and late
stages of disease.
Collectively, together these observations suggest a major
implication of dysfunctions or loss of skin-resident adult
stem/progenitor cells in the development of numerous age-related
skin disorders and carcinogenesis. These studies support then the
therapeutic interest to target these immature and dysfunctional
cells to prevent or treat diverse skin disorders and aggressive skin
cancers that may be promoted with the passage of time. In regard
with this, we described new promising anti-aging and cancer therapeutic strategies consisting of stem cell-based therapies and
molecular targeting of deregulated signalling elements in skin cancer-initiating cells to treat diverse age-associated skin diseases
and cancers in human.

Novel stem cell-based therapies
Novel anti-aging therapies
Modulation of aging process by calorie
restriction and pharmacological agents
Numerous studies have revealed that a nutritious diet, also designated as calorie restriction, use of pharmacological agents including anti-inflammatory and antioxidant compounds and activators
of protein deacetylases such as sirtuins (silent information regulators) may represent the potent therapeutic strategies for improving cell survival and treating diverse metabolic skin disorders [25,
31–34, 212–214]. In fact, calorie restriction or anti-aging skin
cares with these agent types may influence the expression and/or
activity of signalling elements known to be involved in inflammation, oxidative stress, senescence or apoptotic death of skin-resident adult stem/progenitor cells and their progenies during
chronological aging [25, 31, 32]. More specifically, the use of activators of sirtuins, which act as NAD1-dependent protein deacetylases, may modulate the activity of key gene products including
p53 and forkhead box O (FOXOs) family of transcription factors
that are involved in the regulation of cellular metabolism, stress
resistance, senescence and apoptosis. Thereby, the activators of
sirtuins can promote the cell survival and lifespan extension [31,
32, 215]. For instance, the results from a study consisting in a
topical application on the face and neck of a formulation containing 1% yeast Kluyveromyces biopeptides acting as a sirtuin 1 activator carried out with 33 women aged from 37 to 64 years, indicated that this anti-aging skin care significantly improved the
hydration, firmness and pigment colour intensity of skin after 4
weeks of treatment [31]. Moreover, the application of this formulation enriched in yeast Kluyveromyces biopeptides, which
increased the expression levels of nuclear longevity protein sirtuin 1,
also decreased the rate of senescence and apoptotic death
induced by UVB exposure on ex vivo epidermal cell culture
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established from healthy human skin [31]. In the same way, the
use of natural polyphenolic compound, resveratol (trans-3, 49,
5-trihydroxystilbene) found in red wines and diverse plant species
such as grapes, peanuts, berries and pines, as a skin care ingredient, has also been shown to induce the anti-inflammatory and
antioxidant effects and enhance the sirtuin enzymatic activity
[33–37, 216, 217]. More specifically, a topical application of
resveratol may reduce cellular ROS levels and prevent the development of cutaneous disorders such as skin hyperplasia and cancers that may be caused by an UVB light exposure and metabolic
stress during chronological aging [34, 36, 37, 216, 217]. Although
the therapeutic interest to use resveratol in skin care preparations,
it has been reported that this agent, in counterpart, can also potentiate certain types of UVA-induced DNA strand breaks and apoptotic death of immortalized HaCat human keratinocyte cell line in
vitro [218]. On the other hand, the activation of residual hair
bulge-resident melanocyte stem/progenitor cells and/or their early
progenies also may constitute a potential strategy for recovery
melanin-producing melanocytes in hair bulb areas and treatment
of hypopigmentation disorders such as vitiligo and premature hair
greying [152, 219]. For instance, it has been shown that the topical application of purified placental sphingolipid induced an
enhanced MITF expression and its target genes via the stimulation
of p38 stress-signalling pathway that restored follicular melaninproducing melanocytes and hair re-pigmentation in vivo in
C57BL/6J mouse model of age-onset hair greying [152].
Based on these observations, it appears to be important to
more precisely establish the molecular mechanisms associated
with the anti-aging effects induced by calorie restriction, sirtuin
activators and resveratol on skin. Particularly, it will be essential to
estimate their actions on the regenerative capacity and survival of
skin-resident stem/progenitor cells and the maintenance of skin
homeostasis versus their systemic toxicity and tumorigenic potential at long term. The optimization of the administration mode and
therapeutic doses of these anti-aging agents seems also to be necessary before their use in safe conditions in human beings.

Novel cell-replacement and gene therapies
The in vivo stimulation of endogenous skin-resident adult
stem/progenitor cells or use of ex vivo expanded adult
stem/progenitor cells or their differentiated progenies represent
promising strategies for replacing dysfunctional or lost skin aged
cells or obtaining physiologic tissue-engineered human skin
equivalents for skin grafting after intense injuries [2, 38–43, 78,
135, 220]. Several therapeutic strategies have been investigated
for skin reconstructive surgery after intractable and severe
wounds such as burns, deep skin injuries, infections and decubitus ulcers, including cell grafting with diverse biocompatible artificial materials and/or skin fragments [39, 40]. For instance, the
use of skin stem/progenitor cells and their progenies engineering
for expressing human TERT or telomere RNA component (TR)
represents a therapy of great interest for treating the chronological or premature aging disorders such as Werner progenoid syndrome, Fanconi anaemia and chronic dysplastic anaemia which
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are associated with the defects in TERT and/or TR leading a
replicative senescence of skin cells [38, 163]. Consistently, it has
been reported that the bulge-resident ESCs in telomerase-deficient
mice showed an impaired proliferative capacity that led to a
decreased skin and hair growth [163]. The telomerase re-introduction in these mice, however, reversed the functional defects
associated with a decreased telomerase activity and telomere
shortening and restored the long-term survival of mice without
increase skin tumorigenesis [163].
In addition, several data have revealed the beneficial effects to
incorporate the dermal cells or BM-derived stem/progenitor cells
for cell-replacement therapy and skin tissue engineering [39, 41,
78, 139]. The incorporation of dermal sheath cells (DSCs) in skin
equivalents that can secrete diverse cytokines including insulingrowth factor-binding protein-2 (IGFBP-2), has been shown to
enhance the number of putative p63-expressing KSCs, and
improve the epidermal regenerative capacity [78]. Moreover, the
use of cultured autologous BM-derived mesenchymal cells plus
artificial dermis composite graft may also improve mixed
chimerism and vascularized skin graft survival, and thereby promote the recovery of diverse types of intractable dermatopathies
and prevent graft rejection [39]. Similarly, the inclusion of ex vivo
expanded circulating EPCs from an autologous source onto tissue-engineered human skin substitutes has also been shown to
result in the formation of functional microvessels that improved
the perfusion and survival of bioengineered tissues [40].

Novel cancer therapies targeting skin cancer
stem/progenitor cells and their microenvironment
Since the skin stem/progenitor cells appear to provide critical
functions in BCCs, SCCs and melanoma initiation, invasion and
metastasis at distant sites, treatment resistance and disease
relapse, several anti-cancer strategies have been designed to eradicate the total cancer cell mass including skin cancer-initiating
cells and their differentiated progenies. Among the potential
chemopreventive and therapeutic approaches, there are the use of
natural dietary components, specific inhibitors of telomerase,
EGFR, hedgehog, Wnt/b-catenin, Notch, Nodal/Cripto, hyaluronan
(HA)/CD44 and/or SDF-1/CXCR4 signalling cascades and histone
deacetylase (HDAC)-inhibitors as well as the molecular targeting
of anti-apoptotic factors such as Bcl-2 and ABC multidrug transporters (Fig. 3) [1, 83, 192, 202, 221–226]. The results of in vitro
and in vivo studies have revealed a beneficial effect to target these
deregulated signalling elements, alone or in combination therapies, to inhibit the growth, survival, invasion and/or metastasis of
skin cancer cells (Fig. 3) [173, 175, 203, 227–231]. Based on the
observations that the telomerase re-activation may contribute to
cell immortalization and cancer development, including skin cancers, several anti-telomerase strategies have been designed to
inhibit the telomerase activity in cancer cells, and prevent the
tumour development [170, 223, 232–236]. Moreover, the natural
dietary component, resveratol has been shown to act as a potent
chemopreventive and chemotherapeutic agent against the
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chemically- and UVB-induced non-melanoma development by
activating the apoptotic pathways of cell death in mice models of
skin carcinogenesis [35, 36]. Numerous studies have also
revealed the beneficial effects to target the hedgehog signalling
pathway to inhibit the growth and induce the apoptosis of BCC
cells without major toxicity on normal cells [47, 192, 224,
237–239]. Among the hedgehog signalling inhibitor, there are
SMO antagonists including a small molecule CUR61414 and the
plant-derived steroidal alkaloid, cyclopamine or modulators of
sterol levels including 3b-hydroxysteroid (pro-)vitamin D3 and
cholesterol synthesis inhibitors, statins (HMG-CoA reductase
inhibitors) [47, 192, 224, 237–240]. Of particular interest, the data
from a phase 1 clinical trial have also revealed that the treatment
of BCC patients with a hedgehog inhibitor, may reverse the growth
of the tumours in certain patients [241, 242]. Moreover, the inhibition of EGFR and Notch1 signalling using specific EGFR tyrosine
kinase activity inhibitor, AG1478 and g-secretase inhibitor, DAPT
(N-[N-3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester) has also been reported to synergistically induce a substantial rate of apoptotic death of SCC cells [82].
In the case of melanoma, it has been shown that the use of
dominant-negative EGFR, inhibitor of tyrosine kinase activity (TKI)
of EGFR (gefitinib, AG1478 or PD153035) or KIT (imatinib mesylate) as well as the blockade of Wnt5/Frizzeld/protein kinase C,
Notch and Nodal/Cripto-1 cascades induced the cytotoxic effect on
melanoma cells [203, 206, 210, 231, 243–246]. The targeting of
HA/CD44 tumorigenic pathway using mAb or soluble CD44 protein
form also diminished the human melanoma growth and/or incidence of metastases in vitro and in mice models in vivo (Fig. 3)
[230, 247–249]. The pharmacologic suppression of MITF transcription factor expression, which provides critical role in the regulation of differentiation and survival of melanocytic cell lineage
through a topical application of HDAC inhibitor also reduced the
skin pigmentation and melanoma formation in mouse xenografts
derived melanoma cells in vivo [250]. Importantly, the molecular
targeting of sonic hedgehog SHH/PTCH/GLI by using smoothened
co-receptor inhibitor, cyclopamine also prevented the growth,
recurrence, and metastasis of melanoma xenografts in mice in vivo
suggesting that the melanoma-initiating cells may be eliminated
following this treatment type [226]. In this same way, the downregulation of CD133 pentaspan transmembrane glycoprotein (prominin-1) in FEMX-I melanoma cells by short hairpin RNAs was also
accompanied by a reduction of cell growth, cell motility, and capacity of cancer cells to form spheroids in vitro [65]. Moreover, the use
of mAb directed against epitope 1 (AC133 and W6B3C1) or epitope
2 (AC141) of the CD133 protein, induced the cytotoxic effects in
FEMX-I cells in vitro and markedly decreased their metastatic
capacity in mice model in vivo (Fig. 3) [65]. The data from microarray analysis have also revealed that several gene products coding
for Wnt inhibitors were up-regulated in the CD133 down-regulated
cells [65]. These observations suggest then that the signalling
pathway initiated through the CD133 stem cell-like marker can also
contribute to malignant phenotype of melanoma stem cells in
cooperation with Wnt cascade, and thereby constitute a potential
molecular therapeutic target to eradicate the melanoma-initiating

cells. Similarly, it has been reported that the use of a mAb directed
against ABCB5 efflux pump also inhibited the tumour growth of
CD1331/ABCB51 melanoma stem cell-derived xenografts in vivo
1
1
[63]. The ABCB5 blockade in the CD133 /ABCB5 melanoma
stem cell subpopulation was accompanied by an intracellular doxorubicin accumulation that significantly restored drug sensitivity
[58]. Additional characterization of the dose-responses and selectivity of these mAbs on melanoma stem/progenitor cells versus the
normal adult stem cells expressing CD1331/ABCB51 in vitro and
animal models in vivo is however required before their potential
testing in clinical settings in safe conditions.
Other potential therapeutic strategies against invasive,
metastatic and/or relapsed melanomas also include the
immunotherapy-based melanoma vaccines, chemoimmunotherapies with immunosuppressive agents such as interferon-a, gene
therapy and anti-angiogenic therapy by using thalidomine, angiostatin and/or endostatin, without or plus a stem cell-based transplant [112, 221, 227, 251–255]. More particularly, it has been
reported that the melanoma stem cells, including CD1331 clonogenic melanoma cells, express a significant level of cancer testis
antigens (CTAs) suggesting that they could be efficiently targeted
in vivo by CTA-directed immunotherapy [253, 255]. A therapeutic
regimen consisting to 5-fluorocytosine plus engineered neural
stem cells (NSCs) expressing cytosine deaminase, which acts as
a pro-drug activating enzyme, also resulted in a significant reduction in the tumour border in animal models with established
melanoma brain metastasis in vivo [254].

Conclusions and future directions
Altogether, these recent advancements made in the field of skinresident adult stem/progenitor cell biology have provided important information on the deregulated signalling cascades that may
contribute to induce their dysfunctions, loss or malignant transformation during the chronological and accelerated aging and
their pathological consequences. Additional studies are however
necessary to more precisely establish the differentiallyexpressed gene products in these immature cells versus their
differentiated progenies as well as the changes in their microenvironment occurring during human aging process. These future
investigations should shed light onto intrinsic and extrinsic
factors that may contribute to the progressive decline in regenerative capacity or loss of skin-resident adult stem/progenitor
cells, and thereby help to develop new anti-aging strategies for
preventing or delaying the onset of age-related skin disorders in
human beings.
Further identification of specific biomarkers and drug targets
in skin cancer stem/progenitor cells is also essential to more
precisely establish their hierarchical organization and phenotypic
features associated with the skin tumour development and progression from localized cancers in invasive and metastatic stages.
In this regard, the establishment of specific functions of CD133
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protein in normal bulge stem/progenitor cells and melanoma
stem/progenitor cells is of immense interest to identify the copartners that could be selectively targeted in highly tumorigenic
and metastatic melanoma stem cells and without toxicity on normal CD1331 regenerative stem/progenitor cells found in skin and
other tissues. These additional studies should lead to identification
of novel drug targets for eradicating skin tumour- and metastasisinitiating cells, and thereby improving the clinical treatments
against aggressive and recurrent skin cancers, and more

particularly metastatic melanoma, which remain lethal with current therapeutic regimen options.

Acknowledgements
We are supported by grants from the National Institutes of Health
(CA78590, CA111294, CA133774 and CA131944). We thank Ms. Kristi L.
Berger for editing the manuscript.

References
Mimeault M, Bonenfant D, Batra SK. New
advances on the functions of epidermal
growth factor receptor and ceramides in
skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol. 2004; 17:
153–6.
2. Mimeault M, Batra SK. Recent advances
on the significance of stem cells in tissue
regeneration and cancer therapies. Stem
Cells. 2006; 24: 2319–45.
3. McCullough JL, Kelly KM. Prevention and
treatment of skin aging. Ann NY Acad Sci.
2006; 1067: 323–31.
4. Benitah SA. Epidermal stem cells in skin
homeostasis and cutaneous carcinomas.
Clin Transl Oncol. 2007; 9: 760–6.
5. Zouboulis CC, Baron JM, Bohm M, et al.
Frontiers in sebaceous gland biology and
pathology. Exp Dermatol. 2008; 17:
542–51.
6. Muller EJ, Williamson L, Kolly C, et al.
Outside-in signaling through integrins and
cadherins: a central mechanism to control
epidermal growth and differentiation?
J Invest Dermatol. 2008; 128: 501–16.
7. Fuchs E. Skin stem cells: rising to the surface. J Cell Biol. 2008; 180: 273–84.
8. Fuchs E, Horsley V. More than one way to
skin. Genes Dev. 2008; 22: 976–85.
9. Tumbar T, Guasch G, Greco V, et al.
Defining the epithelial stem cell niche in
skin. Science. 2004; 303: 359–63.
10. Webb A, Li A, Kaur P. Location and phenotype of human adult keratinocyte stem
cells of the skin. Differentiation. 2004; 72:
387–95.
11. Larderet G, Fortunel NO, Vaigot P, et al.
Human side population keratinocytes
exhibit long-term proliferative potential
and a specific gene expression profile and
can form a pluristratified epidermis. Stem
Cells. 2006; 24: 965–74.
12. Blanpain C, Lowry WE, Geoghegan A,
et al. Self-renewal, multipotency, and the
existence of two cell populations within an
1.

128

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

epithelial stem cell niche. Cell. 2004; 118:
635–48.
Blanpain C, Fuchs E. Epidermal stem cells
of the skin. Annu Rev Cell Dev Biol. 2006;
22: 339–73.
Ito M, Liu Y, Yang Z, et al. Stem cells in
the hair follicle bulge contribute to wound
repair but not to homeostasis of the epidermis. Nat Med. 2005; 11: 1351–4.
Levy V, Lindon C, Zheng Y, et al.
Epidermal stem cells arise from the hair
follicle after wounding. FASEB J. 2007; 21:
1358–66.
Li L, Xie T. Stem cell niche: Structure and
function. Annu Rev Cell Dev Biol. 2005; 21:
605–31.
Horsley V, O’Carroll D, Tooze R, et al.
Blimp1 defines a progenitor population
that governs cellular input to the sebaceous gland. Cell. 2006; 126: 597–609.
Nishimura EK, Jordan SA, Oshima H, et al.
Dominant role of the niche in melanocyte
stem-cell fate determination. Nature. 2002;
416: 854–60.
Sieber-Blum M, Grim M, Hu YF, et al.
Pluripotent neural crest stem cells in the
adult hair follicle. Dev Dyn. 2004; 231:
258–69.
Yu H, Fang D, Kumar SM, et al. Isolation
of a novel population of multipotent adult
stem cells from human hair follicles. Am J
Pathol. 2006; 168: 1879–88.
Nishimura EK, Granter SR, Fisher DE.
Mechanisms of hair graying: incomplete
melanocyte stem cell maintenance in the
niche. Science. 2005; 307: 720–4.
Benitah SA, Frye M, Glogauer M, et al.
Stem cell depletion through epidermal
deletion of Rac1. Science. 2005; 309:
933–5.
Sharpless NE, DePinho RA. How stem
cells age and why this makes us grow old.
Nat Rev Mol Cell Biol. 2007; 8: 703–13.
Youn SW, Kim DS, Cho HJ, et al. Cellular
senescence induced loss of stem cell pro-

25.

26.

27.

28.

29.

30.

31.

32.

33.

portion in the skin in vitro. J Dermatol Sci.
2004; 35: 113–23.
Pillai S, Oresajo C, Hayward J, et al.
Ultraviolet radiation and skin aging: roles
of reactive oxygen species, inflammation
and protease activation, and strategies for
prevention of inflammation-induced matrix
degradation – a review. Int J Cosmet Sci.
2005; 27: 17–34.
Roh C, Lyle S. Cutaneous stem cells and
wound healing. Pediatr Res. 2006; 59:
100R–3R.
Kwon OS, Yoo HG, Han JH, et al.
Photoaging-associated changes in epidermal proliferative cell fractions in vivo. Arch
Dermatol Res. 2008; 300: 47–52.
Mimeault M, Batra S.K. Recent insights
into the molecular mechanisms involved in
aging and the malignant transformation of
adult stem/progenitor cells and their therapeutic implications. Aging Res Rev. 2009;
8: 94–112.
Chen W, Kang J, Xia J, et al. p53-related
apoptosis resistance and tumor suppression activity in UVB-induced premature
senescent human skin fibroblasts. Int J
Mol Med. 2008; 21: 645–53.
Briganti S, Wlaschek M, Hinrichs C,
et al. Small molecular antioxidants effectively protect from PUVA-induced oxidative
stress responses underlying fibroblast
senescence and photoaging. Free Radic
Biol Med. 2008; 45: 636–44.
Moreau M, Neveu M, Stephan S, et al.
Enhancing cell longevity for cosmetic
application: a complementary approach.
J Drugs Dermatol. 2007; 6: S14–9.
Lavu S, Boss O, Elliott PJ, et al.
Sirtuins–novel therapeutic targets to treat
age-associated diseases. Nat Rev Drug
Discov. 2008; 7: 841–53.
Ingram DK, Zhu M, Mamczarz J, et al.
Calorie restriction mimetics: an emerging
research field. Aging Cell. 2006; 5:
97–108.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 14, No 1-2, 2010
34. Neugebauer RC, Sippl W, Jung M.
Inhibitors of NAD1 dependent histone
deacetylases (sirtuins). Curr Pharm Des.
2008; 14: 562–73.
35. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat
Rev Drug Discov. 2006; 5: 493–506.
36. Athar M, Back JH, Tang X, et al.
Resveratrol: a review of preclinical studies
for human cancer prevention. Toxicol Appl
Pharmacol. 2007; 224: 274–83.
37. Baxter RA. Anti-aging properties of
resveratrol: review and report of a potent
new antioxidant skin care formulation.
J Cosmet Dermatol. 2008; 7: 2–7.
38. Shay JW, Wright WE. Use of telomerase
to create bioengineered tissues. Ann NY
Acad Sci. 2005; 1057: 479–91.
39. Yoshikawa T, Mitsuno H, Nonaka I, et al.
Wound therapy by marrow mesenchymal
cell transplantation. Plast Reconstr Surg.
2008; 121: 860–77.
40. Kung EF, Wang F, Schechner JS. In vivo
perfusion of human skin substitutes with
microvessels formed by adult circulating
endothelial progenitor cells. Dermatol
Surg. 2008; 34: 137–46.
41. Zhang CP, Fu XB. Therapeutic potential of
stem cells in skin repair and regeneration.
Chin J Traumatol. 2008; 11: 209–21.
42. Park BS, Jang KA, Sung JH, et al.
Adipose-derived stem cells and their
secretory factors as a promising therapy
for skin aging. Dermatol Surg. 2008; 34:
1323–6.
43. Branski LK, Gauglitz GG, Herndon DN,
et al. A review of gene and stem cell therapy in cutaneous wound healing. Burns.
2008; 35: 171–80.
44. Chen S, Takahara M, Kido M, et al.
Increased expression of an epidermal stem
cell marker, cytokeratin 19, in cutaneous
squamous cell carcinoma. Br J Dermatol.
2008; 159: 952–5.
45. Lupi O. Correlations between the Sonic
Hedgehog pathway and basal cell carcinoma. Int J Dermatol. 2007; 46: 1113–7.
46. Bachmann IM, Puntervoll HE, Otte AP,
et al. Loss of BMI-1 expression is associated with clinical progress of malignant
melanoma. Mod Pathol. 2008; 21: 583–90.
47. Athar M, Tang X, Lee JL, et al. Hedgehog
signalling in skin development and cancer.
Exp Dermatol. 2006; 15: 667–77.
48. Erb P, Ji J, Kump E, et al. Apoptosis and
pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol.
2008; 624: 283–95.
49. Rass K, Reichrath J. UV damage and DNA
repair in malignant melanoma and non-

50.

51.

52.

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

melanoma skin cancer. Adv Exp Med Biol.
2008; 624: 162–78.
Hussein MR. Ultraviolet radiation and skin
cancer: molecular mechanisms. J Cutan
Pathol. 2005; 32: 191–205.
Pons M, Quintanilla M. Molecular biology
of malignant melanoma and other cutaneous tumors. Clin Transl Oncol. 2006; 8:
466–74.
Pacifico A, Goldberg LH, Peris K, et al.
Loss of CDKN2A and p14ARF expression
occurs frequently in human nonmelanoma
skin cancers. Br J Dermatol. 2008; 158:
291–7.
Liu ZJ, Xiao M, Balint K, et al. Notch1
signaling promotes primary melanoma
progression by activating mitogen-activated protein kinase/phosphatidylinositol
3-kinase-Akt pathways and up-regulating
N-cadherin expression. Cancer Res. 2006;
66: 4182–90.
Chin L. The genetics of malignant
melanoma: lessons from mouse and man.
Nat Rev Cancer. 2003; 3: 559–70.
Tchernev G, Orfanos CE. Downregulation
of cell cycle modulators p21, p27, p53, Rb
and proapoptotic Bcl-2-related proteins
Bax and Bak in cutaneous melanoma is
associated with worse patient prognosis:
preliminary findings. J Cutan Pathol. 2007;
34: 247–56.
Hutchin ME, Kariapper MS, Grachtchouk
M, et al. Sustained Hedgehog signaling is
required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth
cycle. Genes Dev. 2005; 19: 214–23.
Malanchi I, Peinado H, Kassen D, et al.
Cutaneous cancer stem cell maintenance
is dependent on beta-catenin signalling.
Nature. 2008; 452: 650–3.
Frank NY, Margaryan A, Huang Y, et al.
ABCB5-mediated doxorubicin transport
and chemoresistance in human malignant
melanoma. Cancer Res. 2005; 65:
4320–33.
Fang D, Nguyen TK, Leishear K, et al. A
tumorigenic subpopulation with stem cell
properties in melanomas. Cancer Res.
2005; 65: 9328–37.
Dou J, Pan M, Wen P, et al. Isolation and
identification of cancer stem-like cells
from murine melanoma cell lines. Cell Mol
Immunol. 2007; 4: 467–2.
Monzani E, Facchetti F, Galmozzi E, et al.
Melanoma contains CD133 and ABCG2
positive cells with enhanced tumourigenic
potential. Eur J Cancer. 2007; 43: 935–46.
Keshet GI, Goldstein I, Itzhaki O, et al.
MDR1 expression identifies human

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

melanoma stem cells. Biochem Biophys
Res Commun. 2008; 368: 930–6.
Schatton T, Murphy GF, Frank NY, et al.
Identification of cells initiating human
melanomas. Nature. 2008; 451: 345–9.
Grichnik JM, Burch JA, Schulteis RD,
et al. Melanoma, a tumor based on a
mutant stem cell? J Invest Dermatol.
2006; 126: 142–53.
Rappa G, Fodstad O, Lorico A. The stem
cell-associated antigen CD133 (Prominin1) is a molecular therapeutic target for
metastatic melanoma. Stem Cells. 2008;
26: 3008–17.
Ackermann J, Frutschi M, Kaloulis K,
et al. Metastasizing melanoma formation
caused by expression of activated NRasQ61K on an INK4a-deficient background. Cancer Res. 2005; 65: 4005–11.
Lacina L, Dvorankova B, Smetana K,
et al. Marker profiling of normal keratinocytes identifies the stroma from
squamous cell carcinoma of the oral cavity as a modulatory microenvironment in
co-culture. Int J Radiat Biol. 2007; 83:
837–48.
Marsh D, Dickinson S, Neill GW, et al.
alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma
through stromal modulation. Cancer Res.
2008; 68: 3295–303.
Ruiter D, Bogenrieder T, Elder D, et al.
Melanoma-stroma interactions: structural
and functional aspects. Lancet Oncol.
2002; 3: 35–43.
Watt FM. Role of integrins in regulating
epidermal adhesion, growth and differentiation. EMBO J. 2002; 21: 3919–26.
Kloepper JE, Tiede S, Brinckmann J, et al.
Immunophenotyping of the human bulge
region: the quest to define useful in situ
markers for human epithelial hair follicle
stem cells and their niche. Exp Dermatol.
2008; 17: 592–609.
Kamstrup M, Faurschou A, Gniadecki R,
et al. Epidermal stem cells – role in normal, wounded and pathological psoriatic
and cancer skin. Curr Stem Cell Res Ther.
2008; 3: 146–50.
Pellegrini G, Dellambra E, Golisano O,
et al. p63 identifies keratinocyte stem
cells. Proc Natl Acad Sci USA. 2001; 98:
3156–61.
Jost M, Kari C, Rodeck U. The EGF receptor – an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;
10: 505–10.
Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem
and transit-amplifying cells: Lrig1 is a reg-

129

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

130

ulator of stem cell quiescence. Proc Natl
Acad Sci USA. 2006; 103: 11958–63.
Nguyen BC, Lefort K, Mandinova A, et al.
Cross-regulation between Notch and p63
in keratinocyte commitment to differentiation. Genes Dev. 2006; 20: 1028–42.
Devgan V, Nguyen BC, Oh H, et al.
p21WAF1/Cip1 suppresses keratinocyte
differentiation independently of the cell
cycle through transcriptional up-regulation
of the IGF-I gene. J Biol Chem. 2006; 281:
30463–70.
Kim DS, Cho HJ, Yang SK, et al. IGFBP-2
Contributes to the proliferation of less proliferative cells in forming skin equivalents.
Tissue Eng Part A. 2009; 15: 1075–80.
Okuyama R, Ogawa E, Nagoshi H, et al.
p53 homologue, p51/p63, maintains the
immaturity of keratinocyte stem cells by
inhibiting Notch1 activity. Oncogene.
2007; 27: 848–56.
Lechler T, Fuchs E. Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature. 2005;
437: 275–80.
Okuyama R, Lefort K, Dotto GP. A
dynamic model of keratinocyte stem cell
renewal and differentiation: role of the
p21WAF1/Cip1 and Notch1 signaling pathways. J Investig Dermatol Symp Proc.
2004; 9: 248–52.
Lefort K, Mandinova A, Ostano P, et al.
Notch1 is a p53 target gene involved in
human keratinocyte tumor suppression
through negative regulation of ROCK1/2
and MRCKalpha kinases. Genes Dev. 2007;
21: 562–77.
Kolev V, Mandinova A, Guinea-Viniegra
J, et al. EGFR signalling as a negative
regulator of Notch1 gene transcription
and function in proliferating keratinocytes
and cancer. Nat Cell Biol. 2008; 10:
902–11.
Takeda K, Takeuchi O, Tsujimura T, et al.
Limb and skin abnormalities in mice lacking IKKalpha. Science. 1999; 284: 313–6.
Li Q, Lu Q, Estepa G, Verma IM.
Identification of 14–3-3sigma mutation
causing cutaneous abnormality in
repeated-epilation mutant mouse. Proc
Natl Acad Sci USA. 2005; 102: 15977–82.
Richardson RJ, Dixon J, Malhotra S,
et al. Irf6 is a key determinant of the keratinocyte
proliferation-differentiation
switch. Nat Genet. 2006; 38: 1329–34.
Ingraham CR, Kinoshita A, Kondo S, et al.
Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon
regulatory factor 6 (Irf6). Nat Genet. 2006;
38: 1335–40.

88. Zhu F, Xia X, Liu B, et al. IKKalpha shields
14–3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Mol Cell. 2007; 27:
214–27.
89. Liu B, Xia X, Zhu F, et al. IKKalpha is
required to maintain skin homeostasis and
prevent skin cancer. Cancer Cell. 2008; 14:
212–25.
90. Lyle S, Christofidou-Solomidou M, Liu Y,
et al. The C8/144B monoclonal antibody
recognizes cytokeratin 15 and defines the
location of human hair follicle stem cells.
J Cell Sci. 1998; 111 (Pt 21): 3179–
88.
91. Roh C, Tao Q, Photopoulos C, et al.
In vitro differences between keratinocyte
stem cells and transit-amplifying cells of
the human hair follicle. J Invest Dermatol.
2005; 125: 1099–105.
92. Levy V, Lindon C, Harfe BD, et al. Distinct
stem cell populations regenerate the follicle and interfollicular epidermis. Dev Cell.
2005; 9: 855–61.
93. Ito M, Yang Z, Andl T, et al. Wnt-dependent de novo hair follicle regeneration in
adult mouse skin after wounding. Nature.
2007; 447: 316–20.
94. Trempus CS, Morris RJ, Bortner CD, et al.
Enrichment for living murine keratinocytes
from the hair follicle bulge with the cell
surface marker CD34. J Invest Dermatol.
2003; 120: 501–11.
95. Ohyama M, Terunuma A, Tock CL, et al.
Characterization and isolation of stem cellenriched human hair follicle bulge cells.
J Clin Invest. 2006; 116: 249–60.
96. Lee S-H, Chung M-K, Sohn Y-J, et al.
Human hair follicle cells with the cell surface marker CD34 can regenerate new
mouse hair follicles and located in the
outer root sheath of immunodeficient nude
mice. Int J of Stem cells. 2009; 1: 70–81.
97. Flores I, Canela A, Vera E, et al. The
longest telomeres: a general signature of
adult stem cell compartments. Genes Dev.
2008; 22: 654–67.
98. Flores I, Cayuela ML, Blasco MA. Effects
of telomerase and telomere length on epidermal stem cell behavior. Science. 2005;
309: 1253–6.
99. Sarin KY, Cheung P, Gilison D, et al.
Conditional telomerase induction causes
proliferation of hair follicle stem cells.
Nature. 2005; 436: 1048–52.
100. Choi J, Southworth LK, Sarin KY, et al.
TERT promotes epithelial proliferation
through transcriptional control of a Mycand Wnt-related developmental program.
PLoS Genet. 2008; 4: e10.

101. Rajaraman S, Choi J, Cheung P, et al.
Telomere uncapping in progenitor cells
with critical telomere shortening is
coupled to S-phase progression in vivo.
Proc Natl Acad Sci USA. 2007; 104:
17747–52.
102. Ghali L, Wong ST, Green J, et al. Gli1
protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a
subpopulation of mesenchymal cells in
normal human skin. J Invest Dermatol.
1999; 113: 595–9.
103. Huelsken J, Vogel R, Erdmann B, et al.
beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the
skin. Cell. 2001; 105: 533–45.
104. Yamamoto N, Tanigaki K, Han H, et al.
Notch/RBP-J signaling regulates epidermis/hair fate determination of hair
follicular stem cells. Curr Biol. 2003; 13:
333–8.
105. Vidal VP, Chaboissier MC, Lutzkendorf S,
et al. Sox9 is essential for outer root
sheath differentiation and the formation of
the hair stem cell compartment. Curr Biol.
2005; 15: 1340–51.
106. Kasper M, Schnidar H, Neill GW, et al.
Selective modulation of Hedgehog/GLI target gene expression by epidermal growth
factor signaling in human keratinocytes.
Mol Cell Biol. 2006; 26: 6283–98.
107. Gat U, DasGupta R, Degenstein L, et al.
De Novo hair follicle morphogenesis and
hair tumors in mice expressing a truncated
beta-catenin in skin. Cell. 1998; 95:
605–14.
108. Zhang Y, Andl T, Yang SH, et al.
Activation of beta-catenin signaling programs embryonic epidermis to hair follicle
fate. Development. 2008; 135: 2161–72.
109. Estrach S, Ambler CA, Lo CC, et al.
Jagged 1 is a beta-catenin target gene
required for ectopic hair follicle formation
in adult epidermis. Development. 2006;
133: 4427–38.
110. Demehri S, Kopan R. Notch signaling in
bulge stem cells is not required for selection of hair follicle fate. Development.
2009; 136: 891–6.
111. Osawa M, Egawa G, Mak SS, et al.
Molecular characterization of melanocyte
stem cells in their niche. Development.
2005; 132: 5589–99.
112. Chin L, Garraway LA, Fisher DE.
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev.
2006; 20: 2149–82.
113. Grichnik JM. Melanoma, nevogenesis, and
stem cell biology. J Invest Dermatol. 2008;
128: 2365–80.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 14, No 1-2, 2010
114. Na GY, Paek SH, Park BC, et al. Isolation
and characterization of outer root sheath
melanocytes of human hair follicles. Br J
Dermatol. 2006; 155: 902–9.
115. Nishikawa S, Osawa M. Generating quiescent stem cells. Pigment Cell Res. 2007;
20: 263–70.
116. Mak SS, Moriyama M, Nishioka E, et al.
Indispensable role of Bcl2 in the development of the melanocyte stem cell. Dev
Biol. 2006; 291: 144–53.
117. Aubin-Houzelstein G, Djian-Zaouche J,
Bernex F, et al. Melanoblasts’ proper location and timed differentiation depend on
Notch/RBP-J signaling in postnatal hair
follicles. J Invest Dermatol. 2008; 128:
2686–95.
118. Kumano K, Masuda S, Sata M, et al. Both
Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. Pigment
Cell Melanoma Res. 2008; 21: 70–8.
119. Schouwey K, Delmas V, Larue L, et al.
Notch1 and Notch2 receptors influence
progressive hair graying in a dose-dependent manner. Dev Dyn. 2007; 236: 282–9.
120. Moriyama M, Osawa M, Mak SS, et al.
Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and
melanocyte stem cells. J Cell Biol. 2006;
173: 333–9.
121. Belmadani A, Jung H, Ren D, et al. The
chemokine SDF-1/CXCL12 regulates the
migration of melanocyte progenitors in
mouse hair follicles. Differentiation. 2009;
77: 395–411.
122. Yang G, Li Y, Nishimura EK, et al.
Inhibition of PAX3 by TGF-beta modulates
melanocyte viability. Mol Cell. 2008; 32:
554–63.
123. Jeon S, Kim NH, Kim JY, et al. Stem cell
factor induces ERM proteins phosphorylation through PI3K activation to mediate
melanocyte proliferation and migration.
Pigment Cell Melanoma Res. 2009; 22:
77–85.
124. Sieber-Blum M, Grim M. The adult hair
follicle: cradle for pluripotent neural crest
stem cells. Birth Defects Res C Embryo
Today. 2004; 72: 162–72.
125. Hu YF, Zhang ZJ, Sieber-Blum M. An epidermal neural crest stem cell (EPI-NCSC)
molecular signature. Stem Cells. 2006; 24:
2692–702.
126. Yoshida H, Kunisada T, Grimm T, et al.
Review: melanocyte migration and survival
controlled by SCF/c-kit expression.
J Investig Dermatol Symp Proc. 2001;
6: 1–5.
127. Schouwey K, Beermann F. The Notch
pathway: hair graying and pigment cell

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

homeostasis. Histol Histopathol. 2008; 23:
609–19.
Rendl M, Lewis L, Fuchs E. Molecular
Dissection of Mesenchymal-Epithelial
Interactions in the Hair Follicle. PLoS Biol.
2005; 3: 1910–24.
Kawase Y, Yanagi Y, Takato T, et al.
Characterization of multipotent adult stem
cells from the skin: transforming growth
factor-beta (TGF-beta) facilitates cell
growth. Exp Cell Res. 2004; 295: 194–203.
Fernandes KJ, McKenzie IA Mill P, et al.
A dermal niche for multipotent adult skinderived precursor cells. Nat Cell Biol.
2004; 6: 1082–93.
Amoh Y, Li L, Campillo R, et al.
Implanted hair follicle stem cells form
Schwann cells that support repair of severed peripheral nerves. Proc Natl Acad Sci
USA. 2005; 102: 17734–8.
Wong CE, Paratore C, DoursZimmermann MT, et al. Neural crestderived cells with stem cell features can be
traced back to multiple lineages in the
adult skin. J Cell Biol. 2006; 175: 1005–15.
Toma JG, Akhavan M, Fernandes KJ, et al.
Isolation of multipotent adult stem cells
from the dermis of mammalian skin. Nat
Cell Biol. 2001; 3: 778–84.
Belicchi M, Pisati F, Lopa R, et al.
Human skin-derived stem cells migrate
throughout forebrain and differentiate into
astrocytes after injection into adult mouse
brain. J Neurosci Res. 2004; 77: 475–86.
Mimeault M, Hauke R, Batra SK. Stem
cells – A revolution in therapeutics–Recent
advances on the stem cell biology and
their therapeutic applications in regenerative medicine and cancer therapies. Clin
Pharmacol Ther. 2007; 82: 252–64.
Lorenz K, Sicker M, Schmelzer E, et al.
Multilineage differentiation potential of
human dermal skin-derived fibroblasts.
Exp Dermatol. 2008; 17: 925–32.
Zengin E, Chalajour F, Gehling UM, et al.
Vascular wall resident progenitor cells: a
source for postnatal vasculogenesis.
Development. 2006; 133: 1543–51.
Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis.
Am J Physiol Cell Physiol. 2004; 287:
C572–9.
Wu Y, Wang J, Scott PG, et al. Bone marrow-derived stem cells in wound healing: a
review. Wound Repair Regen. 2007; 15:
S18–26.
Fisher GJ, Varani J, Voorhees JJ.
Looking older: fibroblast collapse and therapeutic implications. Arch Dermatol. 2008;
144: 666–72.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

141. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003; 22:
3053–62.
142. Varani J, Dame MK, Rittie L, et al.
Decreased collagen production in chronologically aged skin: roles of age-dependent
alteration in fibroblast function and defective mechanical stimulation. Am J Pathol.
2006; 168: 1861–8.
143. Kang J, Chen W, Xia J, et al. Extracellular
matrix secreted by senescent fibroblasts
induced by UVB promotes cell proliferation
in HaCaT cells through PI3K/AKT and ERK
signaling pathways. Int J Mol Med. 2008;
21: 777–84.
144. Borlon C, Vankoningsloo S, Godard P, et al.
Identification of p53-dependent genes
potentially involved in UVB-mediated premature senescence of human skin fibroblasts using siRNA technology. Mech
Ageing Dev. 2008; 129: 109–19.
145. Wong KK, Maser RS, Bachoo RM, et al.
Telomere dysfunction and Atm deficiency
compromises organ homeostasis and
accelerates ageing. Nature. 2003; 421:
643–8.
146. Calado RT, Young NS. Telomere maintenance and human bone marrow failure.
Blood. 2008; 111: 4446–55.
147. Marrone A, Sokhal P, Walne A, et al.
Functional characterization of novel telomerase RNA (TERC) mutations in patients
with diverse clinical and pathological presentations. Haematologica. 2007; 92:
1013–20.
148. Yamamoto K, Nihrane A, Aglipay J, et al.
Upregulated ATM gene expression and
activated DNA crosslink-induced damage
response checkpoint in Fanconi anemia:
implications for carcinogenesis. Mol Med.
2008; 14: 167–74.
149. Meshorer E, Gruenbaum Y. Gone with the
Wnt/Notch: stem cells in laminopathies,
progeria, and aging. J Cell Biol. 2008; 181:
9–13.
150. Scaffidi P, Misteli T. Lamin A-dependent
misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol.
2008; 10: 452–9.
151. Bergoglio V, Magnaldo T. Nucleotide excision repair and related human diseases.
Genome Dyn. 2006; 1: 35–52.
152. Stout GJ, Blasco MA. Genetic dissection
of the mechanisms underlying telomereassociated diseases: impact of the TRF2
telomeric protein on mouse epidermal
stem cells. Dis Model Mech. 2009; 2:
139–56.
153. Aubert G, Lansdorp PM. Telomeres and
aging. Physiol Rev. 2008; 88: 557–79.

131

154. Mason PJ, Wilson DB, Bessler M.
Dyskeratosis congenita – a disease of dysfunctional telomere maintenance. Curr
Mol Med. 5: 159–70.
155. Kenyon J, Gerson SL. The role of DNA
damage repair in aging of adult stem cells.
Nucleic Acids Res. 2007; 35: 7557–65.
156. Nijnik A, Woodbine L, Marchetti C, et al.
DNA repair is limiting for haematopoietic
stem cells during ageing. Nature. 2007;
447: 686–90.
157. Chigancas V, Lima-Bessa KM, Stary A,
et al. Defective transcription/repair factor
IIH recruitment to specific UV lesions in
trichothiodystrophy syndrome. Cancer
Res. 2008; 68: 6074–83.
158. Redondo P, Prieto J, Munoz IG, et al.
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature. 2008; 456:
107–11.
159. de Gruijl FR, van Kranen HJ, Mullenders
LH, et al. UV-induced DNA damage,
repair, mutations and oncogenic pathways
in skin cancer. J Photochem Photobiol B.
2001; 63: 19–27.
160. Couve-Privat S, Bouadjar B, Avril MF,
et al. Significantly high levels of ultraviolet-specific mutations in the smoothened
gene in basal cell carcinomas from DNA
repair-deficient xeroderma pigmentosum
patients. Cancer Res. 2002; 62: 7186–9.
161. Ya-Grosjean L, Sarasin A. UV-specific
mutations of the human patched gene in
basal cell carcinomas from normal individuals and xeroderma pigmentosum
patients. Mutat Res. 2000; 450: 193–9.
162. Nijhof JG, van Pelt C, Mulder AA, et al.
Epidermal stem and progenitor cells in
murine epidermis accumulate UV damage
despite NER proficiency. Carcinogenesis.
2007; 28: 792–800.
163. Siegl-Cachedenier I, Flores I, Klatt P,
et al. Telomerase reverses epidermal hair
follicle stem cell defects and loss of longterm survival associated with critically
short telomeres. J Cell Biol. 2007; 179:
277–90.
164. Espada J, Varela I, Flores I, et al. Nuclear
envelope defects cause stem cell dysfunction in premature-aging mice. J Cell Biol.
2008; 181: 27–35.
165. Sommer M, Poliak N, Upadhyay S, et al.
DeltaNp63alpha overexpression induces
downregulation of Sirt1 and an accelerated
aging phenotype in the mouse. Cell Cycle.
2006; 5: 2005–11.
166. Bouillet P, Cory S, Zhang LC, et al.
Degenerative disorders caused by Bcl-2
deficiency prevented by loss of its BH3-

132

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

only antagonist Bim. Dev Cell. 2001; 1:
645–53.
Sharpless E, Chin L. The INK4a/ARF locus
and melanoma. Oncogene. 2003; 22:
3092–8.
Lowe SW, Cepero E, Evan G. Intrinsic
tumour suppression. Nature. 2004; 432:
307–15.
Zhao Y, Chaiswing L, Bakthavatchalu V,
et al. Ras mutation promotes p53 activation and apoptosis of skin keratinocytes.
Carcinogenesis. 2006; 27: 1692–8.
Gonzalez-Suarez E, Samper E, Flores
JM, et al. Telomerase-deficient mice with
short telomeres are resistant to skin
tumorigenesis. Nat Genet. 2000; 26:
114–7.
Cosme-Blanco W, Shen MF, Lazar AJ,
et al. Telomere dysfunction suppresses
spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence.
EMBO Rep. 2007; 8: 497–503.
Munoz P, Blanco R, Flores JM, et al. XPF
nuclease-dependent telomere loss and
increased DNA damage in mice overexpressing TRF2 result in premature aging
and cancer. Nat Genet. 2005; 37: 1063–
71.
Lu J, Rho O, Wilker E, et al. Activation of
epidermal akt by diverse mouse skin
tumor promoters. Mol Cancer Res. 2007;
5: 1342–52.
Dahl C, Guldberg P. The genome and
epigenome of malignant melanoma.
APMIS. 2007; 115: 1161–76.
Yang SH, Andl T, Grachtchouk V, et al.
Pathological responses to oncogenic
Hedgehog signaling in skin are dependent
on canonical Wnt/beta-catenin signaling.
Nat Genet. 2008; 40: 1130–5.
Mimeault M, Batra SK. Recent insights
into the molecular mechanisms involved in
aging and the malignant transformation of
adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev. 2009;
8: 94–112.
Kannan K, Sharpless NE, Xu J, et al.
Components of the Rb pathway are critical
targets of UV mutagenesis in a murine
melanoma model. Proc Natl Acad Sci USA.
2003; 100: 1221–5.
Shimizu T, Izumi H, Oga A, et al.
Epidermal growth factor receptor overexpression and genetic aberrations in
metastatic squamous-cell carcinoma of
the skin. Dermatology. 2001; 202: 203–6.
Vidal VP, Ortonne N, Schedl A. SOX9
expression is a general marker of basal cell
carcinoma and adnexal-related neoplasms.
J Cutan Pathol. 2008; 35: 373–9.

180. Tanese K, Fukuma M, Yamada T, et al. Gprotein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol. 2008; 173: 835–43.
181. Aszterbaum M, Rothman A, Johnson RL,
et al. Identification of mutations in the
human PATCHED gene in sporadic basal
cell carcinomas and in patients with the
basal cell nevus syndrome. J Invest
Dermatol. 1998; 110: 885–8.
182. Beachy PA, Karhadkar SS, Berman DM.
Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004; 432: 324–31.
183. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications.
Mod Pathol. 2006; 19: S127–47.
184. Reinisch CM, Uthman A, Erovic BM,
et al. Expression of BMI-1 in normal skin
and inflammatory and neoplastic skin
lesions. J Cutan Pathol. 2007; 34: 174–80.
185. Aszterbaum M, Epstein J, Oro A, et al.
Ultraviolet and ionizing radiation enhance
the growth of BCCs and trichoblastomas in
patched heterozygous knockout mice. Nat
Med. 1999; 5: 1285–91.
186. Mancuso M, Pazzaglia S, Tanori M, et al.
Basal cell carcinoma and its development:
insights from radiation-induced tumors in
Ptch1-deficient mice. Cancer Res. 2004;
64: 934–41.
187. Dahmane N, Lee J, Robins P, et al.
Activation of the transcription factor Gli1
and the Sonic hedgehog signalling pathway in skin tumours. Nature. 1997; 389:
876–81.
188. Fan H, Oro AE, Scott MP, et al. Induction
of basal cell carcinoma features in transgenic human skin expressing Sonic
Hedgehog. Nat Med. 1997; 3: 788–92.
189. Oro AE, Higgins K. Hair cycle regulation of
Hedgehog signal reception. Dev Biol.
2003; 255: 238–48.
190. Grachtchouk V, Grachtchouk M, Lowe L,
et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype.
EMBO J. 2003; 22: 2741–51.
191. Nilsson M, Unden AB, Krause D, et al.
Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing
GLI-1. Proc Natl Acad Sci USA. 2000; 97:
3438–43.
192. Athar M, Li C, Tang X, et al. Inhibition of
smoothened signaling prevents ultraviolet
B-induced basal cell carcinomas through
regulation of Fas expression and apoptosis. Cancer Res. 2004; 64: 7545–52.
193. Nicolas M, Wolfer A, Raj K, et al. Notch1
functions as a tumor suppressor in mouse
skin. Nat Genet. 2003; 33: 416–21.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

J. Cell. Mol. Med. Vol 14, No 1-2, 2010
194. Gailani MR, Bale AE. Developmental
genes and cancer: role of patched in basal
cell carcinoma of the skin. J Natl Cancer
Inst. 1997; 89: 1103–9.
195. Chen KG, Szakacs G, Annereau JP, et al.
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of
the ATP-binding cassette transporter gene
ABCB 5 in melanoma cells and
melanocytes. Pigment Cell Res. 2005; 18:
102–12.
196. Hadnagy A, Gaboury L, Beaulieu R, et al.
SP analysis may be used to identify cancer
stem cell populations. Exp Cell Res. 2006;
312: 3701–10.
197. Klein WM, Wu BP, Zhao S, et al.
Increased expression of stem cell markers
in malignant melanoma. Mod Pathol.
2007; 20: 102–7.
198. Bongiorno MR, Doukaki S, Malleo F,
et al. Identification of progenitor cancer
stem cell in lentigo maligna melanoma.
Dermatol Ther. 2008; 21: S1–5.
199. Strizzi L, Abbott DE, Salomon DS, et al.
Potential for cripto-1 in defining stem celllike characteristics in human malignant
melanoma. Cell Cycle. 2008; 7: 1931–5.
200. Pinnix CC, Herlyn M. The many faces
of Notch signaling in skin-derived cells.
Pigment Cell Res. 2007; 20: 458–
65.
201. Gray-Schopfer VC, Cheong SC, Chong H,
et al. Cellular senescence in naevi and
immortalisation in melanoma: a role for
p16? Br J Cancer. 2006; 95: 496–505.
202. Bardeesy N, Kim M, Xu J, et al. Role of
epidermal growth factor receptor signaling
in RAS-driven melanoma. Mol Cell Biol.
2005; 25: 4176–88.
203. Weeraratna AT, Jiang Y, Hostetter G,
et al. Wnt5a signaling directly affects cell
motility and invasion of metastatic
melanoma. Cancer Cell. 2002; 1: 279–88.
204. Dhomen N, Reis-Filho JS, da Rocha DS,
et al. Oncogenic Braf induces melanocyte
senescence and melanoma in mice.
Cancer Cell. 2009; 15: 294–303.
205. Curtin JA, Fridlyand J, Kageshita T, et al.
Distinct sets of genetic alterations in
melanoma. N Engl J Med. 2005; 353:
2135–47.
206. Curtin JA, Busam K, Pinkel D, et al.
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24:
4340–6.
207. Grafstrom E, Egyhazi S, Ringborg U,
et al. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer
Res. 2005; 11: 2991–7.

208. Poynter JN, Elder JT, Fullen DR, et al.
BRAF and NRAS mutations in melanoma
and melanocytic nevi. Melanoma Res. 16:
267–73.
209. Jonsson G, Dahl C, Staaf J, et al.
Genomic profiling of malignant melanoma
using
tiling-resolution
arrayCGH.
Oncogene. 2007; 26: 4738–48.
210. Smalley KS, Contractor R, Nguyen TK,
et al. Identification of a novel subgroup of
melanomas with KIT/cyclin-dependent
kinase-4 overexpression. Cancer Res.
2008; 68: 5743–52.
211. Quintana E, Shackleton M, Sabel MS,
et al. Efficient tumour formation by single
human melanoma cells. Nature. 2008;
456: 593–8.
212. Metcalf S, Crowson AN, Naylor M, et al.
Imiquimod as an antiaging agent. J Am
Acad Dermatol. 2007; 56: 422–5.
213. Bellizzi D, Rose G, Cavalcante P, et al.
A novel VNTR enhancer within the SIRT3
gene, a human homologue of SIR2, is
associated with survival at oldest ages.
Genomics. 2005; 85: 258–63.
214. Fisher GJ, Wang ZQ, Datta SC, et al.
Pathophysiology of premature skin aging
induced by ultraviolet light. N Engl J Med.
1997; 337: 1419–28.
215. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the
balance towards survival. Trends Cell Biol.
2004; 14: 408–12
216. Mantel C, Broxmeyer HE. Sirtuin 1, stem
cells, aging, and stem cell aging. Curr Opin
Hematol. 15: 326–31.
217. Trapp J, Jung M. The role of NAD1
dependent histone deacetylases (sirtuins)
in ageing. Curr Drug Targets. 2006; 7:
1553–60.
218. Seve M, Chimienti F, Devergnas S, et al.
Resveratrol enhances UVA-induced DNA
damage in HaCaT human keratinocytes.
Med Chem. 2005; 1: 629–33.
219. Davids LM, du Toit E, Kidson SH, et al. A
rare repigmentation pattern in a vitiligo
patient: a clue to an epidermal stem-cell
reservoir of melanocytes? Clin Exp
Dermatol. 2009; 34: 246–8.
220. Yu BD, Mukhopadhyay A, Wong C. Skin
and hair: models for exploring organ
regeneration. Hum Mol Genet. 2008; 17:
R54–9.
221. Gray-Schopfer V, Wellbrock C, Marais R.
Melanoma biology and new targeted therapy. Nature. 2007; 445: 851–7.
222. Mimeault M, Hauke R, Mehta PP, et al.
Recent
advances
on
cancer
stem/progenitor cell research: therapeutic
implications for overcoming resistance to

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

223.

224.

225.

226.

227.

228.

229.

230.

231.

232.

233.
234.

the most aggressive cancers. J Mol Cell
Med. 2007; 11: 981–1011.
Mimeault M, Batra SK. Recent advances
on the development of novel anti-cancer
drugs targeting cancer stem/progenitor
cells. Drug Develop Res. 2008; 69:
415–30.
Tang JY, So PL, Epstein EH Jr. Novel
Hedgehog pathway targets against basal
cell carcinoma. Toxicol Appl Pharmacol.
2006; 224: 257–64.
Singh B, Schneider M, Knyazev P, et al.
UV-induced EGFR signal transactivation is
dependent on proligand shedding by activated metalloproteases in skin cancer cell
lines. Int J Cancer. 2009; 124:
531–9.
Stecca B, Mas C, Clement V, et al.
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between
GLI1 and the RAS-MEK/AKT pathways.
Proc Natl Acad Sci USA. 2007; 104:
5895–00.
Kirkwood JM, Tarhini AA, Panelli MC,
et al. Next generation of immunotherapy
for melanoma. J Clin Oncol. 2008; 26:
3445–55.
Remsberg JR, Lou H, Tarasov SG, et al.
Structural analogues of smoothened intracellular loops as potent inhibitors of
Hedgehog pathway and cancer cell growth.
J Med Chem. 2007; 50: 4534–8.
Chen GS, Yu HS, Lan CC, et al. CXC
chemokine receptor CXCR4 expression
enhances tumorigenesis and angiogenesis
of basal cell carcinoma. Br J Dermatol.
2006; 154: 910–8.
Kim Y, Lee YS, Choe J, et al. CD44-epidermal growth factor receptor interaction
mediates hyaluronic acid-promoted cell
motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive
oxygen species, focal adhesion kinase, and
MMP-2. J Biol Chem. 2008; 283:
22513–28.
Qiu L, Wang Q, Di W, et al. Transient activation of EGFR/AKT cell survival pathway
and expression of survivin contribute to
reduced sensitivity of human melanoma
cells to betulinic acid. Int J Oncol. 2005;
27: 823–30.
Deng Y, Chang S. Role of telomeres and
telomerase in genomic instability, senescence and cancer. Lab Invest. 2007; 87:
1071–6.
Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008; 8: 167–79.
Shay JW, Keith WN. Targeting telomerase
for cancer therapeutics. Br J Cancer. 2008;
98: 677–83.

133

235. Phatak P, Burger AM. Telomerase and its
potential for therapeutic intervention. Br J
Pharmacol. 2007; 152: 1003–11.
236. Cortez-Gonzalez X, Zanetti M. Telomerase
immunity from bench to bedside: round
one. J Transl Med. 2007; 5: 12.
237. Brown AJ. Cholesterol, statins and cancer.
Clin Exp Pharmacol Physiol. 2007; 34:
135–41.
238. Cooper MK, Wassif CA, Krakowiak PA,
et al. A defective response to Hedgehog
signaling in disorders of cholesterol
biosynthesis. Nat Genet. 2003; 33:
508–13.
239. Bijlsma MF, Spek CA, Zivkovic D, et al.
Repression of smoothened by patcheddependent (pro-) vitamin D3 secretion.
PLoS Biol. 2006; 4: e232.
240. Williams JA, Guicherit OM, Zaharian BI,
et al. Identification of a small molecule
inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like
lesions. Proc Natl Acad Sci USA. 2003;
100: 4616–21.
241. Epstein EH. Basal cell carcinomas: attack
of the hedgehog. Nat Rev Cancer. 2008; 8:
743–54.
242. Garber K. Hedgehog drugs begin to show
results. J Natl Cancer Inst. 2008; 100: 692–7.

134

243. Hodi FS, Friedlander P, Corless CL, et al.
Major response to imatinib mesylate in
KIT-mutated melanoma. J Clin Oncol.
2008; 26: 2046–51.
244. Knight LA, Di Nicolantonio F, Whitehouse
P, et al. The in vitro effect of gefitinib
(‘Iressa’) alone and in combination with
cytotoxic chemotherapy on human solid
tumours. BMC Cancer. 2004; 4: 83.
245. Postovit LM, Margaryan NV, Seftor EA,
et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl
Acad Sci USA. 2008; 105: 4329–34.
246. Nickoloff BJ, Hendrix MJ, Pollock PM,
et al. Notch and NOXA-related pathways in
melanoma cells. J Investig Dermatol Symp
Proc. 2005; 10: 95–104.
247. Guo Y, Ma J, Wang J, et al. Inhibition of
human melanoma growth and metastasis
in vivo by anti-CD44 monoclonal antibody.
Cancer Res. 1994; 54: 1561–5.
248. Ahrens T, Sleeman JP, Schempp CM,
et al. Soluble CD44 inhibits melanoma
tumor growth by blocking cell surface
CD44 binding to hyaluronic acid.
Oncogene. 2001; 20: 3399–408.
249. Bartolazzi A, Peach R, Aruffo A, et al.
Interaction between CD44 and hyaluronate

250.

251.

252.

253.

254.

255.

is directly implicated in the regulation of
tumor development. J Exp Med. 1994;
180: 53–66.
Yokoyama S, Feige E, Poling LL, et al.
Pharmacologic suppression of MITF
expression via HDAC inhibitors in the
melanocyte lineage. Pigment Cell
Melanoma Res. 2008; 21: 457–63.
Tsao H, Atkins MB, Sober AJ.
Management of cutaneous melanoma. N
Engl J Med. 2004; 351: 998–1012.
den Brok MH, Nierkens S, Figdor CG,
et al. Dendritic cells: tools and targets for
antitumor vaccination. Expert Rev
Vaccines. 2005; 4: 699–710.
Sigalotti L, Covre A, Zabierowski S, et al.
Cancer testis antigens in human
melanoma stem cells: Expression, distribution, and methylation status. J Cell
Physiol. 2008; 215: 287–91.
Aboody KS, Bush RA, Garcia E, et al.
Development of a tumor-selective
approach to treat metastatic cancer. PLoS
ONE. 2006; 1: e23.
Gedye C, Quirk J, Browning J, et al.
Cancer/testis antigens can be immunological targets in clonogenic CD133(1)
melanoma cells. Cancer Immunol
Immunother. 2009; 58: 1635–46.

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

